<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JBX</journal-id>
<journal-id journal-id-type="hwp">spjbx</journal-id>
<journal-id journal-id-type="nlm-ta">J Biomol Screen</journal-id>
<journal-title>Journal of Biomolecular Screening</journal-title>
<issn pub-type="ppub">1087-0571</issn>
<issn pub-type="epub">1552-454X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1087057111421212</article-id>
<article-id pub-id-type="publisher-id">10.1177_1087057111421212</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epigenetic Drug Discovery</article-title>
<subtitle>Targeting DNA Methyltransferases</subtitle>
</title-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name><surname>Heightman</surname><given-names>Tom</given-names></name>
</contrib>
<contrib contrib-type="guest-editor">
<name><surname>Pope</surname><given-names>Andrew</given-names></name>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Foulks</surname><given-names>Jason M.</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Parnell</surname><given-names>K. Mark</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Nix</surname><given-names>Rebecca N.</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Chau</surname><given-names>Suzanna</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Swierczek</surname><given-names>Krzysztof</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Saunders</surname><given-names>Michael</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Wright</surname><given-names>Kevin</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Hendrickson</surname><given-names>Thomas F.</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Ho</surname><given-names>Koc-Kan</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>McCullar</surname><given-names>Michael V.</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kanner</surname><given-names>Steven B.</given-names></name>
</contrib>
<aff id="aff1-1087057111421212">Astex Pharmaceuticals, Inc., Salt Lake City, UT, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1087057111421212">Steven B. Kanner, PhD, Astex Pharmaceuticals, Inc., 2401 South Foothill Drive, Salt Lake City, UT 84109 E-mail: <email>steven.kanner@astx.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>17</volume>
<issue>1</issue>
<issue-title>Special Issue: Epigenetic-Targeted Drug Discovery, Part II</issue-title>
<fpage>2</fpage>
<lpage>17</lpage>
<history>
<date date-type="received">
<day>31</day>
<month>5</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>7</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>7</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 Society for Laboratory Automation and Screening</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society for Laboratory Automation and Screening</copyright-holder>
</permissions>
<abstract>
<p>Epigenetic modification of DNA leads to changes in gene expression. DNA methyltransferases (DNMTs) comprise a family of nuclear enzymes that catalyze the methylation of CpG dinucleotides, resulting in an epigenetic methylome distinguished between normal cells and those in disease states such as cancer. Disrupting gene expression patterns through promoter methylation has been implicated in many malignancies and supports DNMTs as attractive therapeutic targets. This review focuses on the rationale of targeting DNMTs in cancer, the historical approach to DNMT inhibition, and current marketed hypomethylating therapeutics azacytidine and decitabine. In addition, we address novel DNMT inhibitory agents emerging in development, including CP-4200 and SGI-110, analogs of azacytidine and decitabine, respectively; the oligonucleotides MG98 and miR29a; and a number of reversible inhibitors, some of which appear to be selective against particular DNMT isoforms. Finally, we discuss future opportunities and challenges for next-generation therapeutics.</p>
</abstract>
<kwd-group>
<kwd>DNMT</kwd>
<kwd>epigenetics</kwd>
<kwd>cancer</kwd>
<kwd>methyltransferase</kwd>
<kwd>therapy</kwd>
<kwd>SGI-110</kwd>
<kwd>methylation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1087057111421212" sec-type="intro">
<title>Introduction</title>
<p>For nearly 60 years, it has been recognized that cellular inheritance is controlled by DNA replication during cell division. DNA mutations and gene rearrangements were later discovered to be the driving force behind the evolution of unique organisms. Despite having identical DNA sequences, cells within an organism differentiate into a wide variety of tissues and cell types. The explanation for this phenomenon was built on a proposal that DNA is organized with a complex of proteins into nucleosomes: DNA wrapped 1.67 turns around a histone octamer comprising two molecules each of the common histones H2A, H2B, H3, and H4.<sup><xref ref-type="bibr" rid="bibr1-1087057111421212">1</xref>–<xref ref-type="bibr" rid="bibr4-1087057111421212">4</xref></sup> The discovery that reversible molecular modifications of histones and DNA control gene expression introduced a novel paradigm known as epigenetics.</p>
<p>Recent studies indicate that epigenetic silencing has similar effects as DNA mutations in tumorigenesis.<sup><xref ref-type="bibr" rid="bibr5-1087057111421212">5</xref></sup> In contrast to DNA mutations, epigenetic silencing is a reversible stepwise process, with various levels of control. Transient histone modifications (phospho, methyl, acetyl, ubiquityl, and sumoyl) and more stable DNA methylation lead to the compaction of nucleosomes and formation of transcriptionally inaccessible heterochromatin (<xref ref-type="fig" rid="fig1-1087057111421212"><bold>Fig. 1A</bold></xref>), which needs to be faithfully replicated during cell division to maintain repressive marks (<xref ref-type="fig" rid="fig1-1087057111421212"><bold>Fig. 1B</bold></xref>). Reactivation of genes is also stepwise, resulting in the formation of readily accessible euchromatin. During epigenetic remodeling, many components are required to modify or bind DNA and histones. These concepts have been reviewed extensively.<sup><xref ref-type="bibr" rid="bibr6-1087057111421212">6</xref>–<xref ref-type="bibr" rid="bibr14-1087057111421212">14</xref></sup> This review focuses on the role of human DNA methyltransferases (DNMTs) in cancer as well as the therapeutic potential and challenge of inhibiting DNMTs.</p>
<fig id="fig1-1087057111421212" position="float">
<label>Figure 1.</label>
<caption>
<p>(<bold>A</bold>) Epigenetic silencing through de novo methylation, nucleosome compaction, and histone modification. In the upper left nucleosome, hemi-methylated or un-methylated CpG sites are methylated by DNMT3a or DNMT3b in complex with DNMT3L (bottom left nucleosome), which induces nucleosome compaction (bottom middle nucleosome) by chromatin-modifying complexes (not shown). Epigenetic silencing is also influenced by histone modifications, shown in the upper right and lower right nucleosomes. For simplicity, two possible histone modifications are shown: Histone H3 Lysine 4 methylation (K4me) represents a permissive transcription state (H3K4 can also be di- or trimethylated as marks for transcription enhancers or promoters), whereas Histone H3 Lysine 27 trimethylation (K27me3) represents a repressive transcription state. Note that K27me3 and DNA methylation are mutually exclusive but adjacent within an epigenetically silenced gene. Epigenetic therapy may reverse either silenced or repressed gene expression. (<bold>B</bold>) Maintenance of DNA methylation and histone repressive marks during DNA replication ensures epigenetic silencing after cell division. PCNA recruits DNMT1 to the replication fork, and UHRF1 targets DNMT1 to hemimethylated sites, which are then fully methylated by DNMT1. Epigenetic therapy targeting DNMT1 should reexpress methylation-silenced genes after DNA replication and cell division (not shown).</p>
</caption>
<graphic xlink:href="10.1177_1087057111421212-fig1.tif"/>
</fig>
<sec id="section2-1087057111421212">
<title>DNA methyltransferases</title>
<p>DNA methyltransferases transfer a methyl group from S-adenosyl-methionine (SAM) to the C5 position of the pyrimidine ring of cytosine residues in genomic CpG dinucleotides. CpG dinucleotides are preferentially located in specific regions of the genome, including clusters in gene promoters called CpG islands.<sup><xref ref-type="bibr" rid="bibr15-1087057111421212">15</xref></sup> CpG methylation is crucial for silencing retrotransposon element sequences (i.e., LINE-1 or Alu repeats), X chromosome inactivation, imprinting, regulating gene expression, and cellular transformation.<sup><xref ref-type="bibr" rid="bibr14-1087057111421212">14</xref>–<xref ref-type="bibr" rid="bibr16-1087057111421212">16</xref></sup></p>
<p>There are five DNMT isoforms—DNMT1, DNMT2, DNMT3a, DNMT3b, and DNMT3L—but only DNMT1, 3a, and 3b methylate DNA. DNMT1 is a maintenance methyltransferase, copying methylation marks after DNA replication. This is evident by a preference for hemimethylated DNA as its substrate<sup><xref ref-type="bibr" rid="bibr17-1087057111421212">17</xref>–<xref ref-type="bibr" rid="bibr19-1087057111421212">19</xref></sup> and association with two proteins that assist in methylation maintenance during replication: proliferating cell nuclear antigen (PCNA) and ubiquitin-like plant homeodomain and RING finger domain-containing protein 1 (UHRF-1).<sup><xref ref-type="bibr" rid="bibr20-1087057111421212">20</xref>,<xref ref-type="bibr" rid="bibr21-1087057111421212">21</xref></sup> It has been shown that the PCNA binding domain of DNMT1 enhances but is not required for DNA methylation maintenance.<sup><xref ref-type="bibr" rid="bibr22-1087057111421212">22</xref></sup> In contrast, UHRF-1 is required to maintain DNA methylation by recruiting DNMT1 to hemimethylated DNA near replication forks and damage sites.<sup><xref ref-type="bibr" rid="bibr21-1087057111421212">21</xref></sup> DNMT1 and UHRF-1 deficiency in mice are embryonically lethal<sup><xref ref-type="bibr" rid="bibr23-1087057111421212">23</xref>,<xref ref-type="bibr" rid="bibr24-1087057111421212">24</xref></sup> and result in global loss of DNA methylation in embryonic stem cells, embryos, and mouse embryonic fibroblast (MEF) cells.<sup><xref ref-type="bibr" rid="bibr25-1087057111421212">25</xref>–<xref ref-type="bibr" rid="bibr27-1087057111421212">27</xref></sup> Complete knockout of DNMT1 is catastrophic for the HCT-116 human colon cancer cell line.<sup><xref ref-type="bibr" rid="bibr28-1087057111421212">28</xref>,<xref ref-type="bibr" rid="bibr29-1087057111421212">29</xref></sup></p>
<p>Despite sequence similarity to the DNMT family, DNMT2 does not methylate DNA but instead methylates a specific cytosine in tRNA<sup>Asp</sup> and has been alternatively named tRNA aspartic methyltransferase 1 (TRDMT1).<sup><xref ref-type="bibr" rid="bibr30-1087057111421212">30</xref>,<xref ref-type="bibr" rid="bibr31-1087057111421212">31</xref></sup> DNMT2 null mice are viable and fertile,<sup><xref ref-type="bibr" rid="bibr30-1087057111421212">30</xref></sup> and it remains unclear whether DNMT2 plays a role in human disease.<sup><xref ref-type="bibr" rid="bibr31-1087057111421212">31</xref></sup></p>
<p>DNMT3a and DNMT3b are de novo methyltransferases, initiating DNA methylation marks on unmethylated DNA, and are critical for development and cellular differentiation.<sup><xref ref-type="bibr" rid="bibr32-1087057111421212">32</xref>–<xref ref-type="bibr" rid="bibr34-1087057111421212">34</xref></sup> DNMT3a-deficient mice display organ defects and lethality within weeks after birth with only minor DNA methylation changes.<sup><xref ref-type="bibr" rid="bibr32-1087057111421212">32</xref></sup> DNMT3b-deficient mice are embryonic lethal, suggesting a more significant role of DNMT3b in early development compared to DNMT3a.<sup><xref ref-type="bibr" rid="bibr32-1087057111421212">32</xref></sup> DNMT3b-deficient mice exhibit drastic defects in minor satellite repeat methylation but only minor changes at other common methylation sites.<sup><xref ref-type="bibr" rid="bibr32-1087057111421212">32</xref></sup> Mice deficient for both DNMT3a and DNMT3b are embryonic lethal, and DNMT3a<sup>–/–</sup> DNMT3b<sup>–/–</sup> mouse embryonic fibroblasts display a dramatic loss of de novo methylation activity and changes to global methylation despite the presence of DNMT1.<sup><xref ref-type="bibr" rid="bibr29-1087057111421212">29</xref>,<xref ref-type="bibr" rid="bibr32-1087057111421212">32</xref></sup> It has also been shown that DNMT3a/3b can cooperate with DNMT1 for maintenance methylation.<sup><xref ref-type="bibr" rid="bibr18-1087057111421212">18</xref>,<xref ref-type="bibr" rid="bibr35-1087057111421212">35</xref>–<xref ref-type="bibr" rid="bibr37-1087057111421212">37</xref></sup></p>
<p>Further differences between DNMT3a and 3b functions are evident in conditional germ cell knockout models. DNMT3a and DNMT3b conditional knockout mice are viable, but only offspring from DNMT3a conditional knockout mice die in utero and lack methylation-dependent imprinting, the silencing of maternal or paternal alleles during gametogenesis.<sup><xref ref-type="bibr" rid="bibr38-1087057111421212">38</xref></sup> Thus, although DNMT3a and DNMT3b have overlapping de novo methylation functions, it is clear that DNMT3a is critical for imprinting and germ cells, whereas DNMT3b is more essential for early somatic development.</p>
<p>The remaining DNMT isoform, DNMT3L, shows high homology to DNMT3a and DNMT3b but is catalytically inactive. DNMT3L knockout mice are viable, but both sexes are sterile, and female DNMT3L knockout mice do not produce viable offspring when crossed with wild-type mice.<sup><xref ref-type="bibr" rid="bibr39-1087057111421212">39</xref></sup> Oocytes from DNMT3L-deficient female mice and their heterozygous progeny lack maternal methylation imprints, whereas male germ cells are deficient in paternal methylation imprints.<sup><xref ref-type="bibr" rid="bibr39-1087057111421212">39</xref>,<xref ref-type="bibr" rid="bibr40-1087057111421212">40</xref></sup> Because DNMT3L is catalytically inactive and the other DNMT3 family members are de novo methyltransferases, genetic models were evaluated and revealed a cooperative role of DNM3L and DNMT3a/3b for methylation imprinting.<sup><xref ref-type="bibr" rid="bibr41-1087057111421212">41</xref></sup> Later studies confirmed that DNMT3L binds to and enhances DNMT3b and DNMT3a enzymatic activity.<sup><xref ref-type="bibr" rid="bibr42-1087057111421212">42</xref>,<xref ref-type="bibr" rid="bibr43-1087057111421212">43</xref></sup></p>
</sec>
<sec id="section3-1087057111421212">
<title>DNMT mutations</title>
<p>Mutations in all three catalytically active human DNMT isoforms have been described. Recently, DNMT1 mutations were identified and linked to a form of hereditary sensory and autonomic neuropathy type 1 (HSAN1) with dementia and hearing loss.<sup><xref ref-type="bibr" rid="bibr44-1087057111421212">44</xref></sup> The heterozygous mutations occur in the DNMT1 nuclear targeting region, which is known to be critical for DNMT1 activity.<sup><xref ref-type="bibr" rid="bibr45-1087057111421212">45</xref></sup> Despite the reduction of activity and measurable changes in global methylation, HSAN1 patients with DNMT1 mutations do not show an increased propensity for cancer, countering mouse model evidence that will be discussed later in the review.</p>
<p>DNMT3b mutations have been well characterized as the cause of immunodeficiency, centromere instability, facial anomalies (ICF) syndrome.<sup><xref ref-type="bibr" rid="bibr46-1087057111421212">46</xref></sup> ICF patients have compound, biallelic mutations that reduce DNMT3b methyltransferase activity. Due to the rare occurrence of ICF syndrome (fewer than 50 patients reported worldwide since 1970) and the observed residual methyltransferase activity in the mutated forms of DNMT3b, it is believed that humans with complete functional knockout of DNMT3b may die at birth, similar to the phenotype observed in knockout mice.<sup><xref ref-type="bibr" rid="bibr47-1087057111421212">47</xref></sup> On a cellular level, ICF DNMT3b mutations result in satellite hypomethylation and juxtacentromeric rearrangements of chromosomes 1, 9, and 16. There has been no observed increased risk of cancer with ICF patients, most likely due to a shortened life span because of immunodeficiency, but also possibly due to an upregulation of DNA damage response elements that prevents more rampant genomic instability.<sup><xref ref-type="bibr" rid="bibr48-1087057111421212">48</xref></sup> The distinction could be important since the latter scenario would indicate that therapies targeting DNMT3b may enhance radiation-induced growth inhibition.</p>
<p>Finally, heterozygous DNMT3a mutations have been reported in a subset of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients and correlate with poor prognosis compared to patients lacking DNMT3a mutations.<sup><xref ref-type="bibr" rid="bibr49-1087057111421212">49</xref>,<xref ref-type="bibr" rid="bibr50-1087057111421212">50</xref></sup> AML patients with DNMT3a mutations have residual wild-type expression, do not display global methylation changes, and do not appear to have increased genomic instability based on a normal karyotype and lack of additional mutations, making the oncogenic mechanism unclear. Although more work needs to be done to explore the function of DNMT3a in leukemia, a recent study confirmed the presence of DNMT3a mutations in subtypes of AML patients and found methylation and gene expression changes in the HOXB locus, which has been implicated in oncogenesis.<sup><xref ref-type="bibr" rid="bibr51-1087057111421212">51</xref>–<xref ref-type="bibr" rid="bibr53-1087057111421212">53</xref></sup> Thus, of the known DNMT mutations in humans, only DNMT3a mutations have been implicated in an increased risk for cancer, whereas targeting DNMT1 and DNMT3b for oncological therapy may have less inherent risk of tumorigenesis.</p>
</sec>
<sec id="section4-1087057111421212">
<title>DNA methyltransferases and cancer</title>
<p>DNA methylation profiles in cancer cells are unique from normal, differentiated cells.<sup><xref ref-type="bibr" rid="bibr54-1087057111421212">54</xref>,<xref ref-type="bibr" rid="bibr55-1087057111421212">55</xref></sup> In cancer cells, widespread hypomethylation occurs throughout the genome, and enriched hypermethylation is focused in CpG islands.<sup><xref ref-type="bibr" rid="bibr14-1087057111421212">14</xref>,<xref ref-type="bibr" rid="bibr54-1087057111421212">54</xref>,<xref ref-type="bibr" rid="bibr55-1087057111421212">55</xref></sup> CpG islands are located in the promoters of tumor suppressor genes, including some of the most commonly mutated genes in cancer such as retinoblastoma (Rb), von Hippel-Lindau (VHL), cyclin-dependent kinase inhibitor 2A (CDKN2A, p16), adenomatous polyposis coli (APC), and others listed in <xref ref-type="table" rid="table1-1087057111421212"><bold>Table 1</bold></xref>.</p>
<table-wrap id="table1-1087057111421212" position="float">
<label>Table 1.</label>
<caption>
<p>Tumor Suppressor Genes Silenced by Hypermethylation in Various Cancers and Their Roles in Transformation</p>
</caption>
<graphic alternate-form-of="table1-1087057111421212" xlink:href="10.1177_1087057111421212-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Gene</th>
<th align="center">Tumor Tissue (Hypermethylation Incidence)</th>
<th align="center">Role in Transformation</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>APC</td>
<td>Colon (17%–28%), liver metastasis from colon (42%) breast, lung</td>
<td>Cell proliferation, migration, adhesion, chromosomal stability</td>
<td><xref ref-type="bibr" rid="bibr56-1087057111421212">56</xref>–<xref ref-type="bibr" rid="bibr59-1087057111421212">59</xref></td>
</tr>
<tr>
<td>BRCA1</td>
<td>Breast (13%–15%), metaplastic breast (63%), ovarian (21%)</td>
<td>DNA repair, cell cycle checkpoint, genomic stability</td>
<td><xref ref-type="bibr" rid="bibr59-1087057111421212">59</xref>–<xref ref-type="bibr" rid="bibr62-1087057111421212">62</xref></td>
</tr>
<tr>
<td>CDKN2A (p16)</td>
<td>Colon (30%–40%), head and neck (27%–67%), breast (15%–31%), lung (25%–31%)</td>
<td>Loss of cell cycle checkpoint</td>
<td><xref ref-type="bibr" rid="bibr59-1087057111421212">59</xref>, <xref ref-type="bibr" rid="bibr63-1087057111421212">63</xref>–<xref ref-type="bibr" rid="bibr67-1087057111421212">67</xref></td>
</tr>
<tr>
<td>CDKN2B (p15)</td>
<td>Acute myeloid leukemia (71%–94%), chronic myeloid leukemia (24%)</td>
<td>Loss of cell cycle checkpoint</td>
<td><xref ref-type="bibr" rid="bibr59-1087057111421212">59</xref>, <xref ref-type="bibr" rid="bibr68-1087057111421212">68</xref>, <xref ref-type="bibr" rid="bibr69-1087057111421212">69</xref></td>
</tr>
<tr>
<td>E-cadherin</td>
<td>Thyroid (83%), breast, prostate</td>
<td>Cell proliferation, invasion, metastasis</td>
<td><xref ref-type="bibr" rid="bibr70-1087057111421212">70</xref>, <xref ref-type="bibr" rid="bibr71-1087057111421212">71</xref></td>
</tr>
<tr>
<td>ER</td>
<td>Breast (25% in estrogen receptor negative), prostate (80%–95%), lung, leukemia</td>
<td>Hormone resistance</td>
<td><xref ref-type="bibr" rid="bibr72-1087057111421212">72</xref>–<xref ref-type="bibr" rid="bibr77-1087057111421212">77</xref></td>
</tr>
<tr>
<td>MLH1</td>
<td>Endometrial (91%), gastric (95%–100%), colon (9%–15%), ovarian secondary tumors (56%)</td>
<td>DNA mismatch repair, gene mutations, microsatellite instability</td>
<td><xref ref-type="bibr" rid="bibr59-1087057111421212">59</xref>, <xref ref-type="bibr" rid="bibr78-1087057111421212">78</xref>–<xref ref-type="bibr" rid="bibr83-1087057111421212">83</xref></td>
</tr>
<tr>
<td>RASSF1A</td>
<td>Lung (34%–70%), breast (9%), ovarian (10%–50%), kidney (23%)</td>
<td>Cell proliferation</td>
<td><xref ref-type="bibr" rid="bibr84-1087057111421212">84</xref>, <xref ref-type="bibr" rid="bibr85-1087057111421212">85</xref></td>
</tr>
<tr>
<td>Rb</td>
<td>Retinoblastoma (10%–13%), nervous system tumors (19%)</td>
<td>Cell proliferation</td>
<td><xref ref-type="bibr" rid="bibr86-1087057111421212">86</xref>–<xref ref-type="bibr" rid="bibr88-1087057111421212">88</xref></td>
</tr>
<tr>
<td>VHL</td>
<td>Renal (10%–19%)</td>
<td>Stability of oncogenic proteins</td>
<td><xref ref-type="bibr" rid="bibr89-1087057111421212">89</xref>, <xref ref-type="bibr" rid="bibr90-1087057111421212">90</xref></td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Silencing of tumor suppressor genes through DNA methylation has been proposed as a “second hit” for cellular transformation, equivalent to mutations or translocations.<sup><xref ref-type="bibr" rid="bibr5-1087057111421212">5</xref></sup> Related to this, methylation-induced silencing occurs in genes relevant to a particular cancer progression: estrogen receptor (ER) in breast cancer, breast cancer type 1 susceptibility protein (BRCA1) in breast and ovarian cancer, mutL homolog 1 (MLH1) in colon cancer, and so on.<sup><xref ref-type="bibr" rid="bibr91-1087057111421212">91</xref></sup></p>
<p>Studies in mice with APC deficiency have revealed a role for DNMTs in the formation of colon tumors. APCmin mice develop intestinal neoplasias, but APCmin/DNMT1<sup>+/–</sup> mice exhibit reduced frequency of intestinal neoplasia.<sup><xref ref-type="bibr" rid="bibr92-1087057111421212">92</xref></sup> APCmin/DNMT3b<sup>–/–</sup> mice also develop fewer intestinal neoplasms but develop the same amount of early stage adenomas as APCmin mice, implicating DNMT3b for later stage tumor growth.<sup><xref ref-type="bibr" rid="bibr93-1087057111421212">93</xref></sup> Overexpression of DNMT3b, but not DNMT3a, in APCmin mice promoted tumorigenesis and increased methylation of the tumor suppressor genes SFRP2, SFRP4, and SFRP5 but did not alter methylation states for APC, MLH1, or p16, suggesting that gene-specific methylation occurs during tumorigenesis.<sup><xref ref-type="bibr" rid="bibr94-1087057111421212">94</xref></sup></p>
<p>Mounting evidence suggests that microRNAs (miRNA), small noncoding RNAs that alter gene expression, can be regulated by DNA methylation and can indirectly regulate cancer-relevant gene expression.<sup><xref ref-type="bibr" rid="bibr95-1087057111421212">95</xref></sup> One particular miRNA, mir-124a, is hypermethylated in acute lymphoblastic leukemia (ALL) patients and reexpressed following treatment with a hypomethylating agent.<sup><xref ref-type="bibr" rid="bibr96-1087057111421212">96</xref></sup> In addition, reexpression of mir-124a correlated with silencing of its target CDK6, a protein involved in the Rb pathway.<sup><xref ref-type="bibr" rid="bibr97-1087057111421212">97</xref></sup> Thus, methylation changes may result in a cascade of downstream effectors that may alter cancer progression.</p>
<p>DNMT1 and DNMT3b are overexpressed and amplified in numerous cancers.<sup><xref ref-type="bibr" rid="bibr98-1087057111421212">98</xref></sup> Initial studies with DNMT1 knockout in HCT-116 cells revealed a cooperative role for DNMT3b because only DNMT1/DNMT3b double knockouts displayed altered methylation levels and slowed proliferation.<sup><xref ref-type="bibr" rid="bibr35-1087057111421212">35</xref></sup> Tumor xenograft growth is also reduced in the double knockout cells when compared to parental cells.<sup><xref ref-type="bibr" rid="bibr99-1087057111421212">99</xref></sup> It was later discovered that the original DNMT1 knockout was a hypomorph and that complete DNMT1 knockout is catastrophic for the HCT-116 cancer cell line.<sup><xref ref-type="bibr" rid="bibr28-1087057111421212">28</xref>,<xref ref-type="bibr" rid="bibr29-1087057111421212">29</xref></sup> Interestingly, DNMT1-deficient mouse embryonic fibroblasts require multiple cell divisions for apoptosis to occur, suggesting that cancer cells may be more reliant on DNMT1 activity than normal cells for survival.<sup><xref ref-type="bibr" rid="bibr26-1087057111421212">26</xref></sup></p>
<p>Alternative splice variants of DNMT3b also are upregulated in cancers and alter DNA methylation patterns despite the fact that some are catalytically inactive.<sup><xref ref-type="bibr" rid="bibr100-1087057111421212">100</xref>–<xref ref-type="bibr" rid="bibr103-1087057111421212">103</xref></sup> It is unclear how these truncated DNMT3b isoforms affect normal DNMT3b function and contribute to oncogenesis. Perhaps overexpression of catalytically inactive DNMT3b plays a role in the global hypomethylation phenotype observed in cancer cells.<sup><xref ref-type="bibr" rid="bibr14-1087057111421212">14</xref></sup></p>
<p>A concern of inhibiting DNMTs is on-target toxicity and oncogenic events that may be the result of retrotransposon reactivation, genomic instability, or spontaneous immortalization.<sup><xref ref-type="bibr" rid="bibr104-1087057111421212">104</xref>–<xref ref-type="bibr" rid="bibr106-1087057111421212">106</xref></sup> These and other studies have indicated that low levels of DNMT1 lead to hypomethylation, even lower levels induce genomic instability,<sup><xref ref-type="bibr" rid="bibr107-1087057111421212">107</xref></sup> and complete knockout is lethal.<sup><xref ref-type="bibr" rid="bibr108-1087057111421212">108</xref></sup> Although these observations are alarming, studies with MDS patients treated with nucleoside analog hypomethylating agents have not revealed an increase in chromosomal instability above normal levels,<sup><xref ref-type="bibr" rid="bibr109-1087057111421212">109</xref></sup> and normal cells with lower proliferation capacity are less sensitive to hypomethylating agents.<sup><xref ref-type="bibr" rid="bibr110-1087057111421212">110</xref>,<xref ref-type="bibr" rid="bibr111-1087057111421212">111</xref></sup> In addition, the potential oncogenic effects of hypomethylation may actually sensitize cancer cells to apoptosis through genomic instability or enhance immune-targeted cell death through expression of tumor antigens.<sup><xref ref-type="bibr" rid="bibr112-1087057111421212">112</xref></sup></p>
<p>The following sections summarize the current DNMT targeting agents that have been tested preclinically and those that are approved commercially. Although two DNMT inhibitors are currently approved to treat MDS, there are potential advantages for creating new generations of inhibitors to improve drug properties, eliminate the need for DNA incorporation, and target solid tumors. The key will be to find the appropriate therapeutic window and identify combinations that may limit toxicity and avoid oncogenesis.</p>
</sec></sec>
<sec id="section5-1087057111421212">
<title>Past and Current Approaches to DNMT Inhibition</title>
<sec id="section6-1087057111421212">
<title>Nucleoside analogs</title>
<p>Historically, the first compounds that demonstrated DNA hypomethylation activity in cells were cytidine analogs: 5<bold>-</bold>Azacytidine/VIDAZA (AZA) and 5-Aza-2′-deoxycytidine/DACOGEN (DAC)<sup><xref ref-type="bibr" rid="bibr113-1087057111421212">113</xref></sup> (<xref ref-type="fig" rid="fig2-1087057111421212"><bold>Fig. 2A</bold></xref>). Both compounds are imported by cells, converted to the activated triphosphate 5-Aza-dCTP, and subsequently incorporated into DNA. The presence of a nitrogen at the 5 position of the azacytidine nucleobase results in an irreversible covalent complex with DNMT1<sup><xref ref-type="bibr" rid="bibr114-1087057111421212">114</xref></sup> and triggers proteasome-mediated DNMT1 degradation<sup><xref ref-type="bibr" rid="bibr115-1087057111421212">115</xref></sup> (<xref ref-type="fig" rid="fig3-1087057111421212"><bold>Fig. 3</bold></xref>). In AML cell lines, DNMT1 levels are dramatically reduced with 100 nM DAC or 1 µM AZA. DNA hypomethylation is observed at even lower concentrations (30 nM DAC or 300 nM AZA).<sup><xref ref-type="bibr" rid="bibr116-1087057111421212">116</xref>,<xref ref-type="bibr" rid="bibr117-1087057111421212">117</xref></sup> The difference in potency between DAC and AZA stems from the diversion of AZA, which is also converted to the ribonucleoside triphosphate, 5-Aza-CTP, into RNA.<sup><xref ref-type="bibr" rid="bibr118-1087057111421212">118</xref></sup></p>
<fig id="fig2-1087057111421212" position="float">
<label>Figure 2.</label>
<caption>
<p>Structures of compounds with reported DNA methyltransferase (DNMT) inhibitory activity. (<bold>A</bold>) Nucleoside analogs that inhibit DNMT once incorporated into DNA. (<bold>B</bold>) Compounds proposed to inhibit DNMT reversibly</p>
</caption>
<graphic xlink:href="10.1177_1087057111421212-fig2.tif"/></fig>
<fig id="fig3-1087057111421212" position="float">
<label>Figure 3.</label>
<caption>
<p>(<bold>A</bold>) Molecular mechanism of cytosine methylation by DNA methyltransferase (DNMT). (<bold>B</bold>) Molecular mechanism of DNMT inhibition by DNA incorporated decitabine or azacytidine. The formation of a covalent DNMT–DNA complex leads to DNMT degradation and subsequent hypomethylation of CpG sites throughout the genome. Adapted from Santi et al.<sup><xref ref-type="bibr" rid="bibr114-1087057111421212">114</xref></sup> Glu, glutamine; SAM, <italic>S</italic>-adenosyl-L-methionine; Ado, adenosyl; Met, methionine; SAH, <italic>S</italic>-adenosyl-L-homocysteine</p>
</caption>
<graphic xlink:href="10.1177_1087057111421212-fig3.tif"/></fig>
<p>The potent DNA hypomethylation activities of DAC and AZA disappear at higher concentrations (~3–10 µM).<sup><xref ref-type="bibr" rid="bibr116-1087057111421212">116</xref>,<xref ref-type="bibr" rid="bibr117-1087057111421212">117</xref></sup> The U-shaped dose–response curve for hypomethylation reflects cytotoxicity that is unrelated to DNA methylation, resulting in diminished DNA incorporation of DAC and AZA.<sup><xref ref-type="bibr" rid="bibr116-1087057111421212">116</xref></sup> Most of the early clinical trials of AZA and DAC used dosages that were based on maximum tolerated doses that may not have effectively decreased DNA methylation.<sup><xref ref-type="bibr" rid="bibr119-1087057111421212">119</xref>–<xref ref-type="bibr" rid="bibr121-1087057111421212">121</xref></sup> The early clinical trials were designed to test the potential cytotoxic effect of the inhibitors rather than whether DNMT inhibition would be an effective cancer therapeutic modality.</p>
<p>In the past decade, clinical trials in MDS and AML have employed low doses of AZA and DAC along with treatment schedules that allow for efficient DNA incorporation with minimal toxicity and have shown clear clinical benefits. AZA was approved by the U.S. Food and Drug Administration (FDA) in 2004 for the treatment of MDS, based on a primary phase III trial where patients treated with AZA showed an improvement in objective response rates and a reduction in transfusion requirements relative to best supportive care. In the primary AZA registration study, the response rate in the AZA group was 16% (6% complete response and 10% partial response), and there were no responses in the best supportive care arm.<sup><xref ref-type="bibr" rid="bibr122-1087057111421212">122</xref>–<xref ref-type="bibr" rid="bibr124-1087057111421212">124</xref></sup> A subsequent European phase III trial showed significant improvement in median overall survival: 24.5 months with AZA versus 15.0 months with conventional care regimens.<sup><xref ref-type="bibr" rid="bibr125-1087057111421212">125</xref></sup> AZA has been granted marketing authorization by the European Commission for patients with high-risk MDS and AML.</p>
<p>DAC was also approved for MDS treatment in 2006, based on an objective response rate and transfusion independence in a randomized phase III study where DAC was compared to best supportive care. In the DAC registration study, patients in the DAC treatment arm showed an objective response rate of 16% (15% complete response rate and 1% partial response).<sup><xref ref-type="bibr" rid="bibr126-1087057111421212">126</xref></sup> Using preclinical findings that showed optimal DNA hypomethylation with low-dose prolonged exposure to DAC,<sup><xref ref-type="bibr" rid="bibr127-1087057111421212">127</xref></sup> subsequent clinical trials showed significantly improved results, including 39% complete responses,<sup><xref ref-type="bibr" rid="bibr128-1087057111421212">128</xref></sup> and an overall improvement rate of 51%.<sup><xref ref-type="bibr" rid="bibr129-1087057111421212">129</xref></sup> Similar results were observed in a recent phase II study of DAC in older patients with AML, including a 27% complete response rate.<sup><xref ref-type="bibr" rid="bibr130-1087057111421212">130</xref></sup> The clinical benefits of DAC appear to be mechanism specific, as clinical response in MDS has been shown to correlate strongly with DNA hypomethylation.<sup><xref ref-type="bibr" rid="bibr131-1087057111421212">131</xref></sup></p>
<p>On the basis of success of AZA and DAC in hematological disease, clinicians are now using the low-dose, prolonged exposure treatments pioneered in MDS clinical trials in a solid tumor setting. A recent phase I study using DAC in combination with carboplatin in platinum-resistant ovarian cancer showed promising results, including complete responses and stable disease as well as DNA hypomethylation in peripheral blood mononuclear cells.<sup><xref ref-type="bibr" rid="bibr132-1087057111421212">132</xref></sup> A phase II combination study of AZA and the histone deacetylase inhibitor, Entinostat, in advanced non–small cell lung cancer is also under way, with early results indicating that 30% of the first 28 patients on the trial are responding to treatment.<sup><xref ref-type="bibr" rid="bibr133-1087057111421212">133</xref></sup></p>
<p>Despite the advantages of AZA and DAC, significant challenges stem from the instability of both compounds in aqueous solutions as well as in vivo deamination by cytidine deaminase. Efforts to circumvent problems of metabolic instability have yielded two different analogs of DAC: NPEOC<bold>-</bold>DAC and SGI-110 (previously called S110). NPEOC-DAC contains a moiety that protects the exocyclic amine of DAC. However, the compound was no more potent than DAC in vivo.<sup><xref ref-type="bibr" rid="bibr134-1087057111421212">134</xref></sup> SGI-110 is a dinucleotide that includes a deoxyguanosine (5′-DACpG-3′) and is largely resistant to cytidine deaminase.<sup><xref ref-type="bibr" rid="bibr135-1087057111421212">135</xref></sup> SGI-110 has shown activity in cancer xenograft models,<sup><xref ref-type="bibr" rid="bibr136-1087057111421212">136</xref></sup> has exhibited DNA hypomethylation activity in primates,<sup><xref ref-type="bibr" rid="bibr137-1087057111421212">137</xref></sup> and is currently being studied in a phase I clinical trial focused in patients with MDS and AML.</p>
<p>In addition to improving the stability of the azanucleosides, efforts are under way to improve cellular delivery. CP-4200 is an elaidic acid ester analog of AZA designed to render the drug less dependent on conventional nucleoside transport systems and has shown superior efficacy to AZA in an orthotopic ALL mouse tumor model.<sup><xref ref-type="bibr" rid="bibr138-1087057111421212">138</xref></sup></p>
</sec>
<sec id="section7-1087057111421212">
<title>Other nucleoside analogs</title>
<p>In addition to 5-Aza-C and 5-Aza-CdR, other cytidine analogs have been shown to inhibit DNMT activity once incorporated into DNA. Among these is 5,6-dihydroazacytidine (5,6-dihydro-AZA), which has demonstrated DNA hypomethylation activity in cells, albeit with 10-fold less potency than AZA.<sup><xref ref-type="bibr" rid="bibr113-1087057111421212">113</xref></sup> The low cell-based activity of 5,6-dihydro-AZA can be attributed to its inefficient conversion to the activated deoxyribonucleoside triphosphate, leading to poor DNA incorporation.<sup><xref ref-type="bibr" rid="bibr139-1087057111421212">139</xref></sup> 5-Fluoro-2′-deoxycytidine (5F-dC), when incorporated into DNA, inhibits DNMT1 through an irreversible covalent complex similar to AZA and DAC.<sup><xref ref-type="bibr" rid="bibr140-1087057111421212">140</xref>,<xref ref-type="bibr" rid="bibr141-1087057111421212">141</xref></sup> The cellular metabolism of 5F-CdR does not result in its conversion to 5F-dCTP or subsequent DNA incorporation, instead being converted to 5-fluoro-2′-deoxyuridylate, an inhibitor of thymidylate synthetase.<sup><xref ref-type="bibr" rid="bibr142-1087057111421212">142</xref></sup> Zebularine-incorporated DNA also inhibits DNMT1 through a covalent, though reversible, complex.<sup><xref ref-type="bibr" rid="bibr141-1087057111421212">141</xref></sup> Similar to 5,6-dihydro-Aza-C, high concentrations of zebularine (~50 µM) are required to observe DNMT1 inhibition in cells due to inefficient incorporation into DNA.<sup><xref ref-type="bibr" rid="bibr143-1087057111421212">143</xref></sup></p>
</sec>
<sec id="section8-1087057111421212">
<title>Oligonucleotides</title>
<p>MG98, a 20-bp antisense oligonucleotide, was developed to prevent the translation of DNMT1. The sequence is complementary with the 3′-UTR of the DNMT1 mRNA and has shown DNMT inhibitory activity in a preclinical xenograft model.<sup><xref ref-type="bibr" rid="bibr144-1087057111421212">144</xref></sup> Unfortunately, clinical trials using MG98 have failed to demonstrate activity.<sup><xref ref-type="bibr" rid="bibr145-1087057111421212">145</xref>–<xref ref-type="bibr" rid="bibr147-1087057111421212">147</xref></sup> miR29a, a microRNA that targets DNMT1 and DNMT3a/b, has been shown to reduce DNA methylation in cells.<sup><xref ref-type="bibr" rid="bibr148-1087057111421212">148</xref></sup></p>
</sec>
<sec id="section9-1087057111421212">
<title>Reversible inhibitors</title>
<p>Despite the successes of AZA and DAC, there is significant need for DNMT inhibitors that do not rely on DNA incorporation for activity. A recent study using a panel of human cancer cell lines showed a 1000-fold variability in DAC potency, attributed to differential incorporation of DAC into DNA.<sup><xref ref-type="bibr" rid="bibr149-1087057111421212">149</xref></sup> As DNA hypomethylation correlates with clinical benefit of DAC in MDS,<sup><xref ref-type="bibr" rid="bibr131-1087057111421212">131</xref></sup> it is possible that some element of MDS resistance to AZA and DAC stems from the ability of tumor cells to block the import, phosphorylation, and incorporation of the drugs into DNA. Nonincorporating inhibitors could bypass these hurdles by targeting DNMT directly.</p>
<p>Nonincorporating DNMT inhibitors may offer a large therapeutic window, compared to the U-shaped dose–response curve for DAC and AZA limited by cytotoxicity and lack of DNA incorporation at high concentrations.<sup><xref ref-type="bibr" rid="bibr116-1087057111421212">116</xref>,<xref ref-type="bibr" rid="bibr117-1087057111421212">117</xref></sup> In addition, the development of selective compounds for DNMT1, DNMT3a, and DNMT3b would facilitate targeting of diseases driven by a particular DNMT enzyme, with minimal off-target effects. Selective DNMT inhibitors would also have value as tool compounds to understand the biological roles of the individual DNA methyltransferases.</p>
<p>A number of small molecules have been reported to inhibit DNA methylation, either through in vitro biochemical or cell-based assays. Although the following list is not exhaustive, it demonstrates the diversity of compounds that were reported to inhibit DNMT activity (<xref ref-type="fig" rid="fig2-1087057111421212"><bold>Fig. 2B</bold></xref>).</p>
<p>Hydralazine is a cardiovascular drug that was shown to inhibit DNA methylation in cells,<sup><xref ref-type="bibr" rid="bibr150-1087057111421212">150</xref>–<xref ref-type="bibr" rid="bibr152-1087057111421212">152</xref></sup> although not in an in vitro biochemical assay.<sup><xref ref-type="bibr" rid="bibr152-1087057111421212">152</xref></sup> The DNMT inhibitory activity of hydralazine is controversial, as a subsequent study was unable to reproduce DNMT inhibitory activity in cells.<sup><xref ref-type="bibr" rid="bibr153-1087057111421212">153</xref>,<xref ref-type="bibr" rid="bibr154-1087057111421212">154</xref></sup> Clinical studies of hydralazine in combination with a histone deacetylase inhibitor (valproate) in MDS are under way.<sup><xref ref-type="bibr" rid="bibr155-1087057111421212">155</xref></sup></p>
<p>Procainamide is another cardiovascular drug with apparent activity against DNMT in cells.<sup><xref ref-type="bibr" rid="bibr150-1087057111421212">150</xref>,<xref ref-type="bibr" rid="bibr151-1087057111421212">151</xref></sup> Like hydralazine, however, the DNA methylation inhibition of procainamide in cells has been disputed.<sup><xref ref-type="bibr" rid="bibr153-1087057111421212">153</xref></sup> Procaine, a closely related molecule, has also been reported to inhibit DNA methylation in cells,<sup><xref ref-type="bibr" rid="bibr156-1087057111421212">156</xref></sup> although this effect was not confirmed by an independent follow-up study.<sup><xref ref-type="bibr" rid="bibr157-1087057111421212">157</xref></sup></p>
<p>(–)-Epigallocatechin-3-gallate (EGCG), a major component of green tea extracts, has been shown to inhibit DNA methylation in vitro using nuclear extracts, presumably through binding to DNMT1, as well as alterations in methylation status and reexpression of tumor suppressor genes.<sup><xref ref-type="bibr" rid="bibr158-1087057111421212">158</xref></sup> Subsequent studies, however, failed to confirm DNMT inhibition with EGCG.<sup><xref ref-type="bibr" rid="bibr153-1087057111421212">153</xref>,<xref ref-type="bibr" rid="bibr157-1087057111421212">157</xref></sup></p>
<p>RG108 is a small-molecule inhibitor of DNMT1 that was discovered using a computational screening approach.<sup><xref ref-type="bibr" rid="bibr159-1087057111421212">159</xref></sup> The compound blocked DNA methyltransferase activity in vitro and in cells inhibited the methylation of tumor suppressor gene promoter DNA, but not DNA in centromeric satellite elements, suggesting a context-dependent DNA methylation inhibition.<sup><xref ref-type="bibr" rid="bibr160-1087057111421212">160</xref></sup> RG108, unlike the nucleoside analogs AZA, DAC, zebularine, procaine, and EGCG, did not demonstrate cytotoxic or genotoxic effects on cells even at high concentrations.<sup><xref ref-type="bibr" rid="bibr157-1087057111421212">157</xref></sup></p>
<p>The antibiotic mithramycin A was shown to reduce methylation at tumor suppressor gene CpG islands and reactivate the tumor suppressor genes in cells. In addition, treatment with the drug resulted in DNMT1 depletion as well as decreased mobility of cancer cells.<sup><xref ref-type="bibr" rid="bibr161-1087057111421212">161</xref></sup></p>
<p>SGI-1027, a quinoline-based compound, has demonstrated inhibitory activity against DNMT1, DNMT3a, and DNMT3b in biochemical assays and resulted in decreased methylation at tumor suppressor gene CpG islands and corresponding gene upregulation.<sup><xref ref-type="bibr" rid="bibr162-1087057111421212">162</xref></sup></p>
<p>Nanaomycin A is an antibiotic that was recently reported to selectively inhibit DNMT3B, dramatically inhibit cytosine methylation in cells, and result in the reexpression of RASSF1A, a tumor suppressor gene.<sup><xref ref-type="bibr" rid="bibr163-1087057111421212">163</xref></sup> Other DNMT–isoform selective compounds have also been recently described, including DNMT3B-selective NSC 14778 and DNMT1-selective NSC 106084.<sup><xref ref-type="bibr" rid="bibr164-1087057111421212">164</xref></sup></p>
<p>At first glance, there appear to be few underlying similarities between the various published DNMT inhibitors. As efforts to directly target DNMT enzymes mature, there will be a need for rigorous biochemical and biophysical characterization of DNMT inhibitors that is, as yet, lacking for the compounds discussed above. We have found that compounds that bind to DNA, such as the intercalator ethidium bromide, can potently inhibit DNMT enzymatic assays (unpublished data), highlighting the need for careful characterization of screening hits. However, the potential clinical benefits of reversible DNMT inhibitors justify any required validation efforts.</p>
</sec></sec>
<sec id="section10-1087057111421212">
<title>Challenges and Opportunities for DNMT Therapy Development</title>
<p>The discovery and development of novel pharmaceuticals targeting DNMTs faces significant challenges. These include but are not limited to identification of inhibitors that do not incorporate into or bind to DNA, effects of competing with SAM binding or other cofactors, how specific DNMT inhibitors will perform in the context of the cell cycle dependency of DNMT function, development of resistance mechanisms in tumors, and whether global changes in methylation will cause genomic instability, allelic imbalances, and retrotransposon reactivation. In addition, optimal pharmaceutical properties of novel inhibitors will be vital given the potential for toxicities associated with DNMT inhibition and whether drug stability issues or confounding metabolite generation will affect maintenance of methylation patterns and concomitant gene reexpression in tumors versus normal tissues. Despite these challenges and given the success of marketed hypomethylating drugs, targeting DNMTs remains an attractive approach for the development of novel cancer therapies.</p>
<p>The approach of directly inhibiting DNMTs with nonnucleoside inhibitors offers an opportunity to selectively inhibit different members of the DNMT family of enzymes. The X-ray crystal structure of the human DNMT3a/3L complex was first published in 2007, and more recently, the X-ray structures of both human and mouse DNMT1 were described.<sup><xref ref-type="bibr" rid="bibr43-1087057111421212">43</xref>,<xref ref-type="bibr" rid="bibr165-1087057111421212">165</xref></sup> However, no DNMT structures in complex with small-molecule inhibitors, other than with the cofactor reaction product S-adenosyl-homocysteine (SAH), have been reported. These structures should assist in the screening, discovery, and development of novel inhibitors targeting DNMTs. A list of small-molecule DNMT inhibitors discovered to date, including those described above (<xref ref-type="fig" rid="fig2-1087057111421212"><bold>Fig. 2</bold></xref>), can be found in public databases (ChEMBL and The Binding Database).<sup><xref ref-type="bibr" rid="bibr166-1087057111421212">166</xref>,<xref ref-type="bibr" rid="bibr167-1087057111421212">167</xref></sup></p>
<p>Many inhibitors with a structure–activity relationship (SAR) around blockade of DNMT1 or DNMT3b activity have been described and offer the opportunity to explore refined effects on the hypomethylation of the genome through the blockade of de novo methylation, maintenance methylation, or both.<sup><xref ref-type="bibr" rid="bibr168-1087057111421212">168</xref>,<xref ref-type="bibr" rid="bibr169-1087057111421212">169</xref></sup> The potential advantage of separate selective inhibitors for DNMT1 and DNMT3b clinically would enable the titration of drugs to these targets depending on the tumor type and potentially balance any toxicity that each drug may engender. Targeting of DNMT3a may provide alternative hypomethylating effects, but two recent reports indicate that DNMT3a mutations that may be functionally inactivating occur in AML, suggesting that blockade of that enzyme could promote tumor formation after long-term inhibitor treatment.<sup><xref ref-type="bibr" rid="bibr50-1087057111421212">50</xref>,<xref ref-type="bibr" rid="bibr51-1087057111421212">51</xref></sup> Additional effective inhibitors may be those that concomitantly inhibit DNMT1 and DNMT3 enzymes and could have efficacy similar to the nucleoside analogs. A nonnucleoside pan-DNMT inhibitor may phenocopy the effects observed by AZA or DAC without incorporation into DNA, thereby reducing the potential for chromosomal instability and bone marrow toxicity related to DNA damage. Avoidance of dose-limiting myelotoxicity through direct DNMT inhibition may support combination treatments with chemotherapeutic agents. Induced chromatin remodeling may lead to secondary tumors due to modulation of DNA methylation patterns as observed in DNMT1 genetically altered mice.<sup><xref ref-type="bibr" rid="bibr104-1087057111421212">104</xref>,<xref ref-type="bibr" rid="bibr105-1087057111421212">105</xref></sup> Ideally, novel inhibitors of DNMTs would not bind to or incorporate into DNA since intercalation or minor groove binding may lead to genomic instability and potential toxicity and would mediate their effects through competition with SAM binding and catalytic disruption. Studies have demonstrated that normal cells are relatively resistant to AZA and DAC treatment, in part due to their reduced proliferative capacity.<sup><xref ref-type="bibr" rid="bibr110-1087057111421212">110</xref>,<xref ref-type="bibr" rid="bibr111-1087057111421212">111</xref></sup> Direct inhibition of DNMTs with nonnucleoside drugs should correspondingly have limited toxicity in normal tissues.</p>
<p>Understanding how individual nonnucleoside inhibitors of DNMT1, DNMT3, or combination drugs specifically affect promoter methylation, gene expression, and tumor growth will be critical for clinical assessment of efficacy. Knowing which CpG sites are affected by hypomethylation through blockade of the different enzymes, as well as to what degree demethylation results in transcriptional modulation of specific functional genes, will facilitate biomarker development. Another challenge involves whether reversible or covalent inhibitors should be developed and how these different approaches will affect the clinical therapeutic window. These challenges await the discovery of broader genomic methylation and expression patterns in tumors, combined with innovation in fragment-based chemistry approaches and docking-based virtual screening of enzyme active sites.<sup><xref ref-type="bibr" rid="bibr169-1087057111421212">169</xref></sup></p>
<p>Another complicating factor in the development of DNMT inhibitors is the contribution of the nucleosome and its associated histone marks in the expression of genes.<sup><xref ref-type="bibr" rid="bibr14-1087057111421212">14</xref>,<xref ref-type="bibr" rid="bibr170-1087057111421212">170</xref></sup> The reexpression of genes following hypomethylation of DNA requires the eviction of nucleosomes from gene promoters. Treatment of cells with DAC led to demethylation of CpG islands, but not all of them had a corresponding loss of nucleosomes upstream of transcription start sites.<sup><xref ref-type="bibr" rid="bibr171-1087057111421212">171</xref></sup> Unmethylated promoters with intact nucleosomes were repressed despite DNA hypomethylation, possibly due to Polycomb repressor complexes that silence gene transcription through changes in specific histone marks known collectively as PRC reprogramming.<sup><xref ref-type="bibr" rid="bibr14-1087057111421212">14</xref>,<xref ref-type="bibr" rid="bibr170-1087057111421212">170</xref>,<xref ref-type="bibr" rid="bibr172-1087057111421212">172</xref></sup> Inhibitors of DNMT1, DNMT3, or both may lead to promoter and gene body hypomethylation but may not in all cases lead to reexpression of tumor suppressor genes, miRNAs, and other functional genes important in tumor biology. The plasticity of CpG methylation within promoters and gene bodies is both heritable and stochastic, and inhibitors will likely have effects on individual CpG sites differently. Thus, therapeutic combinations of specific DNMT inhibitors together with drugs that target histone modifications may offer an approach to address the tumor epigenome as a whole. Alternatively, targeting enzymes such as the histone methyltransferase SET7/9 or the histone demethylase LSD1 that regulate DNMT1 stability may result in a pronounced epigenetic effect.<sup><xref ref-type="bibr" rid="bibr173-1087057111421212">173</xref>,<xref ref-type="bibr" rid="bibr174-1087057111421212">174</xref></sup></p>
<p>Recent examples of combination epigenetic targeting in clinical trials, including evaluation of AZA or DAC with histone deacetylase (HDAC) inhibitors, have been reviewed previously.<sup><xref ref-type="bibr" rid="bibr168-1087057111421212">168</xref>,<xref ref-type="bibr" rid="bibr175-1087057111421212">175</xref></sup> Overall, there have been limited clinical synergies from these combinations in hematological malignancies or solid tumors, possibly due to dosing schedules, selection of the most appropriate cancer indications, or stage of disease. A better understanding of both global and specific hypomethylation and acetylation patterns induced by treatments with DNMT + HDAC inhibitors compared to the clinical response is warranted. Since HDAC inhibitors affect acetylation of nuclear histones, cytoplasmic p53, and other targets, the effects of these drugs are complex and may modulate both tumor cell survival and differentiation pathways. Additional clinical studies will help to identify when epigenetic drug combinations will be most effective, particularly when tumor debulking approaches should be combined with antimetastatic or anticancer stem cell therapies. Combinations between SGI-110 and other drugs may offer advantages in both dosing schedule and drug deposition in tumors compared with DAC or AZA. Furthermore, profiling of tumor methylation status will help to stratify patients with respect to treatment selection and associated risks.<sup><xref ref-type="bibr" rid="bibr175-1087057111421212">175</xref></sup></p>
<p>Drug combination approaches also have included epigenetic targeting together with either conventional chemotherapy or selective therapies such as Gleevec.<sup><xref ref-type="bibr" rid="bibr168-1087057111421212">168</xref></sup> The conclusions from these trials included both improved clinical benefit and hypomethylation of specific gene promoters,<sup><xref ref-type="bibr" rid="bibr176-1087057111421212">176</xref>-<xref ref-type="bibr" rid="bibr180-1087057111421212">180</xref></sup> opening the possibility for evaluation of yet untested combinations. Current strategies include combinations of hypomethylating agents with biologics, including Vectibix, Rituxan, Avastin, or pegylated-IFN-α2b, as well as small molecules such as Velcade or Nexavar (clinicaltrials.gov). As the development of new inhibitors of specific DNMTs and other epigenetic targets emerges,<sup><xref ref-type="bibr" rid="bibr181-1087057111421212">181</xref></sup> the opportunities for testing combinations of epigenetic drugs together or combined with appropriate targeted therapies that approach different signaling pathways in tumors will expand significantly.<sup><xref ref-type="bibr" rid="bibr182-1087057111421212">182</xref></sup> Epigenetic drug development will continue to enhance the armamentarium of therapies useful in the treatment of a variety of malignancies, which will ultimately address the significant unmet need remaining in the field.</p>
</sec>
</body>
<back>
<ack><p>The authors thank Jeremy Lamb for his instrumental help with the figures and Stuart Hwang for suggestions and critical review.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-1087057111421212">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kornberg</surname><given-names>R. D.</given-names></name>
</person-group> <article-title>Chromatin Structure: A Repeating Unit of Histones and DNA</article-title>. <source>Science</source> <year>1974</year>, <volume>184</volume>, <fpage>868</fpage>–<lpage>871</lpage>.</citation>
</ref>
<ref id="bibr2-1087057111421212">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klug</surname><given-names>A.</given-names></name>
<name><surname>Rhodes</surname><given-names>D.</given-names></name>
<name><surname>Smith</surname><given-names>J.</given-names></name>
<name><surname>Finch</surname><given-names>J. T.</given-names></name>
<name><surname>Thomas</surname><given-names>J. O.</given-names></name>
</person-group> <article-title>A Low Resolution Structure for the Histone Core of the Nucleosome</article-title>. <source>Nature</source> <year>1980</year>, <volume>287</volume>, <fpage>509</fpage>–<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr3-1087057111421212">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arents</surname><given-names>G.</given-names></name>
<name><surname>Burlingame</surname><given-names>R. W.</given-names></name>
<name><surname>Wang</surname><given-names>B. C.</given-names></name>
<name><surname>Love</surname><given-names>W. E.</given-names></name>
<name><surname>Moudrianakis</surname><given-names>E. N.</given-names></name>
</person-group> <article-title>The Nucleosomal Core Histone Octamer at 3.1 A Resolution: A Tripartite Protein Assembly and a Left-Handed Superhelix</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source>. <year>1991</year>, <volume>88</volume>, <fpage>10148</fpage>–<lpage>10152</lpage>.</citation>
</ref>
<ref id="bibr4-1087057111421212">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luger</surname><given-names>K.</given-names></name>
<name><surname>Mader</surname><given-names>A. W.</given-names></name>
<name><surname>Richmond</surname><given-names>R. K.</given-names></name>
<name><surname>Sargent</surname><given-names>D. F.</given-names></name>
<name><surname>Richmond</surname><given-names>T. J.</given-names></name>
</person-group> <article-title>Crystal Structure of the Nucleosome Core Particle at 2.8 A Resolution</article-title>. <source>Nature</source> <year>1997</year>, <volume>389</volume>, <fpage>251</fpage>–<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr5-1087057111421212">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herman</surname><given-names>J. G.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
</person-group> <article-title>Gene Silencing in Cancer in Association with Promoter Hypermethylation</article-title>. <source>N. Engl. J. Med</source>. <year>2003</year>, <volume>349</volume>, <fpage>2042</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr6-1087057111421212">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
<name><surname>Laird</surname><given-names>P. W.</given-names></name>
</person-group> <article-title>Cancer Epigenetics Comes of Age</article-title>. <source>Nat. Genet</source>. <year>1999</year>, <volume>21</volume>, <fpage>163</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr7-1087057111421212">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kirmizis</surname><given-names>A.</given-names></name>
<name><surname>Bartley</surname><given-names>S. M.</given-names></name>
<name><surname>Kuzmichev</surname><given-names>A.</given-names></name>
<name><surname>Margueron</surname><given-names>R.</given-names></name>
<name><surname>Reinberg</surname><given-names>D.</given-names></name>
<name><surname>Green</surname><given-names>R.</given-names></name>
<name><surname>Farnham</surname><given-names>P. J.</given-names></name>
</person-group> <article-title>Silencing of Human Polycomb Target Genes Is Associated with Methylation of Histone H3 Lys 27</article-title>. <source>Genes Dev</source>. <year>2004</year>, <volume>18</volume>, <fpage>1592</fpage>–<lpage>1605</lpage>.</citation>
</ref>
<ref id="bibr8-1087057111421212">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laird</surname><given-names>P. W.</given-names></name>
</person-group> <article-title>Cancer Epigenetics</article-title>. <source>Hum. Mol. Genet</source>. <year>2005</year>, <volume>14</volume>(<issue>Spec No 1</issue>), <fpage>R65</fpage>–<lpage>R76</lpage>.</citation>
</ref>
<ref id="bibr9-1087057111421212">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bird</surname><given-names>A.</given-names></name>
</person-group> <article-title>Perceptions of Epigenetics</article-title>. <source>Nature</source> <year>2007</year>, <volume>447</volume>, <fpage>396</fpage>–<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr10-1087057111421212">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>E.</given-names></name>
<name><surname>Shilatifard</surname><given-names>A.</given-names></name>
</person-group> <article-title>The A, B, Gs of Silencing</article-title>. <source>Genes Dev</source>. <year>2007</year>, <volume>21</volume>, <fpage>1141</fpage>–<lpage>1144</lpage>.</citation>
</ref>
<ref id="bibr11-1087057111421212">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gibney</surname><given-names>E. R.</given-names></name>
<name><surname>Nolan</surname><given-names>C. M.</given-names></name>
</person-group> <article-title>Epigenetics and Gene Expression</article-title>. <source>Heredity</source> <year>2010</year>, <volume>105</volume>, <fpage>4</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr12-1087057111421212">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Szyf</surname><given-names>M.</given-names></name>
</person-group> <article-title>A Dynamic Methylome: Implications of Non-CG Methylation/Demethylation</article-title>. <source>Cell Cycle</source> <year>2010</year>, <volume>9</volume>, <fpage>3846</fpage>–<lpage>3847</lpage>.</citation>
</ref>
<ref id="bibr13-1087057111421212">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Upadhyay</surname><given-names>A. K.</given-names></name>
<name><surname>Cheng</surname><given-names>X.</given-names></name>
</person-group> <article-title>Dynamics of Histone Lysine Methylation: Structures of Methyl Writers and Erasers</article-title>. <source>Prog. Drug Res</source>. <year>2011</year>, <volume>67</volume>, <fpage>107</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr14-1087057111421212">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taberlay</surname><given-names>P. C.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>DNA Methylation and Cancer</article-title>. <source>Prog. Drug Res</source>. <year>2011</year>, <volume>67</volume>, <fpage>1</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr15-1087057111421212">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miranda</surname><given-names>T. B.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>DNA Methylation: The Nuts and Bolts of Repression</article-title>. <source>J. Cell Physiol</source>. <year>2007</year>, <volume>213</volume>, <fpage>384</fpage>–<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr16-1087057111421212">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
<name><surname>Ohm</surname><given-names>J. E.</given-names></name>
</person-group> <article-title>Epigenetic Gene Silencing in Cancer: A Mechanism for Early Oncogenic Pathway Addiction?</article-title> <source>Nat. Rev. Cancer</source> <year>2006</year>, <volume>6</volume>, <fpage>107</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr17-1087057111421212">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pedrali-Noy</surname><given-names>G.</given-names></name>
<name><surname>Weissbach</surname><given-names>A.</given-names></name>
</person-group> <article-title>Mammalian DNA Methyltransferases Prefer Poly(dI-dC) as Substrate</article-title>. <source>J. Biol. Chem</source>. <year>1986</year>, <volume>261</volume>, <fpage>7600</fpage>–<lpage>7602</lpage>.</citation>
</ref>
<ref id="bibr18-1087057111421212">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>GD.</given-names></name>
<name><surname>Ni</surname><given-names>J.</given-names></name>
<name><surname>Kelesoglu</surname><given-names>N.</given-names></name>
<name><surname>Roberts</surname><given-names>R. J.</given-names></name>
<name><surname>Pradhan</surname><given-names>S.</given-names></name>
</person-group> <article-title>Co-operation and Communication between the Human Maintenance and De Novo DNA (cytosine-5) Methyltransferases</article-title>. <source>EMBO J</source>. <year>2002</year>, <volume>21</volume>, <fpage>4183</fpage>–<lpage>4195</lpage>.</citation>
</ref>
<ref id="bibr19-1087057111421212">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ross</surname><given-names>J. P.</given-names></name>
<name><surname>Suetake</surname><given-names>I.</given-names></name>
<name><surname>Tajima</surname><given-names>S.</given-names></name>
<name><surname>Molloy</surname><given-names>P. L.</given-names></name>
</person-group> <article-title>Recombinant Mammalian DNA Methyltransferase Activity on Model Transcriptional Gene Silencing Short RNA-DNA Heteroduplex Substrates</article-title>. <source>Biochem. J</source>. <year>2010</year>, <volume>432</volume>, <fpage>323</fpage>–<lpage>332</lpage>.</citation>
</ref>
<ref id="bibr20-1087057111421212">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chuang</surname><given-names>L. S.</given-names></name>
<name><surname>Ian</surname><given-names>H. I.</given-names></name>
<name><surname>Koh</surname><given-names>T. W.</given-names></name>
<name><surname>Ng</surname><given-names>H. H.</given-names></name>
<name><surname>Xu</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>B. F.</given-names></name>
</person-group> <article-title>Human DNA-(Cytosine-5) Methyltransferase-PCNA Complex as a Target for p21WAF1</article-title>. <source>Science</source> <year>1997</year>, <volume>277</volume>, <fpage>1996</fpage>–<lpage>2000</lpage>.</citation>
</ref>
<ref id="bibr21-1087057111421212">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bostick</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>J. K.</given-names></name>
<name><surname>Esteve</surname><given-names>P. O.</given-names></name>
<name><surname>Clark</surname><given-names>A.</given-names></name>
<name><surname>Pradhan</surname><given-names>S.</given-names></name>
<name><surname>Jacobsen</surname><given-names>S. E.</given-names></name>
</person-group> <article-title>UHRF1 Plays a Role in Maintaining DNA Methylation in Mammalian Cells</article-title>. <source>Science</source> <year>2007</year>, <volume>317</volume>, <fpage>1760</fpage>–<lpage>1764</lpage>.</citation>
</ref>
<ref id="bibr22-1087057111421212">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spada</surname><given-names>F.</given-names></name>
<name><surname>Haemmer</surname><given-names>A.</given-names></name>
<name><surname>Kuch</surname><given-names>D.</given-names></name>
<name><surname>Rothbauer</surname><given-names>U.</given-names></name>
<name><surname>Schermelleh</surname><given-names>L.</given-names></name>
<name><surname>Kremmer</surname><given-names>E.</given-names></name>
<name><surname>Carell</surname><given-names>T.</given-names></name>
<name><surname>Langst</surname><given-names>G.</given-names></name>
<name><surname>Leonhardt</surname><given-names>H.</given-names></name>
</person-group> <article-title>DNMT1 but Not Its Interaction with the Replication Machinery Is Required for Maintenance of DNA Methylation in Human Cells</article-title>. <source>J. Cell Biol</source>. <year>2007</year>, <volume>176</volume>, <fpage>565</fpage>–<lpage>571</lpage>.</citation>
</ref>
<ref id="bibr23-1087057111421212">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>E.</given-names></name>
<name><surname>Bestor</surname><given-names>T. H.</given-names></name>
<name><surname>Jaenisch</surname><given-names>R.</given-names></name>
</person-group> <article-title>Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality</article-title>. <source>Cell</source> <year>1992</year>, <volume>69</volume>, <fpage>915</fpage>–<lpage>926</lpage>.</citation>
</ref>
<ref id="bibr24-1087057111421212">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muto</surname><given-names>M.</given-names></name>
<name><surname>Kanari</surname><given-names>Y.</given-names></name>
<name><surname>Kubo</surname><given-names>E.</given-names></name>
<name><surname>Takabe</surname><given-names>T.</given-names></name>
<name><surname>Kurihara</surname><given-names>T.</given-names></name>
<name><surname>Fujimori</surname><given-names>A.</given-names></name>
<name><surname>Tatsumi</surname><given-names>K.</given-names></name>
</person-group> <article-title>Targeted Disruption of Np95 Gene Renders Murine Embryonic Stem Cells Hypersensitive to DNA Damaging Agents and DNA Replication Blocks</article-title>. <source>J. Biol. Chem</source>. <year>2002</year>, <volume>277</volume>, <fpage>34549</fpage>–<lpage>34555</lpage>.</citation>
</ref>
<ref id="bibr25-1087057111421212">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lei</surname><given-names>H.</given-names></name>
<name><surname>Oh</surname><given-names>S. P.</given-names></name>
<name><surname>Okano</surname><given-names>M.</given-names></name>
<name><surname>Juttermann</surname><given-names>R.</given-names></name>
<name><surname>Goss</surname><given-names>K. A.</given-names></name>
<name><surname>Jaenisch</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
</person-group> <article-title>De Novo DNA Cytosine Methyltransferase Activities in Mouse Embryonic Stem Cells</article-title>. <source>Development</source> <year>1996</year>, <volume>122</volume>, <fpage>3195</fpage>–<lpage>3205</lpage>.</citation>
</ref>
<ref id="bibr26-1087057111421212">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jackson-Grusby</surname><given-names>L.</given-names></name>
<name><surname>Beard</surname><given-names>C.</given-names></name>
<name><surname>Possemato</surname><given-names>R.</given-names></name>
<name><surname>Tudor</surname><given-names>M.</given-names></name>
<name><surname>Fambrough</surname><given-names>D.</given-names></name>
<name><surname>Csankovszki</surname><given-names>G.</given-names></name>
<name><surname>Dausman</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>P.</given-names></name>
<name><surname>Wilson</surname><given-names>C.</given-names></name>
<name><surname>Lander</surname><given-names>E.</given-names></name><etal/>
</person-group>. <article-title>Loss of Genomic Methylation Causes p53-Dependent Apoptosis and Epigenetic Deregulation</article-title>. <source>Nat. Genet</source>. <year>2001</year>, <volume>27</volume>, <fpage>31</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr27-1087057111421212">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharif</surname><given-names>J.</given-names></name>
<name><surname>Muto</surname><given-names>M.</given-names></name>
<name><surname>Takebayashi</surname><given-names>S.</given-names></name>
<name><surname>Suetake</surname><given-names>I.</given-names></name>
<name><surname>Iwamatsu</surname><given-names>A.</given-names></name>
<name><surname>Endo</surname><given-names>T. A.</given-names></name>
<name><surname>Shinga</surname><given-names>J.</given-names></name>
<name><surname>Mizutani-Koseki</surname><given-names>Y.</given-names></name>
<name><surname>Toyoda</surname><given-names>T.</given-names></name>
<name><surname>Okamura</surname><given-names>K.</given-names></name><etal/>
</person-group>. <article-title>The SRA Protein Np95 Mediates Epigenetic Inheritance by Recruiting Dnmt1 to Methylated DNA</article-title>. <source>Nature</source> <year>2007</year>, <volume>450</volume>, <fpage>908</fpage>–<lpage>912</lpage>.</citation>
</ref>
<ref id="bibr28-1087057111421212">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Egger</surname><given-names>G.</given-names></name>
<name><surname>Jeong</surname><given-names>S.</given-names></name>
<name><surname>Escobar</surname><given-names>S. G.</given-names></name>
<name><surname>Cortez</surname><given-names>C. C.</given-names></name>
<name><surname>Li</surname><given-names>T. W.</given-names></name>
<name><surname>Saito</surname><given-names>Y.</given-names></name>
<name><surname>Yoo</surname><given-names>C. B.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
<name><surname>Liang</surname><given-names>G.</given-names></name>
</person-group> <article-title>Identification of DNMT1 (DNA Methyltransferase 1) Hypomorphs in Somatic Knockouts Suggests an Essential Role for DNMT1 in Cell Survival</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source>. <year>2006</year>, <volume>103</volume>, <fpage>14080</fpage>–<lpage>14085</lpage>.</citation>
</ref>
<ref id="bibr29-1087057111421212">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>T.</given-names></name>
<name><surname>Hevi</surname><given-names>S.</given-names></name>
<name><surname>Gay</surname><given-names>F.</given-names></name>
<name><surname>Tsujimoto</surname><given-names>N.</given-names></name>
<name><surname>He</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Ueda</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
</person-group> <article-title>Complete Inactivation of DNMT1 Leads to Mitotic Catastrophe in Human Cancer Cells</article-title>. <source>Nat. Genet</source>. <year>2007</year>, <volume>39</volume>, <fpage>391</fpage>–<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr30-1087057111421212">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goll</surname><given-names>M. G.</given-names></name>
<name><surname>Kirpekar</surname><given-names>F.</given-names></name>
<name><surname>Maggert</surname><given-names>K. A.</given-names></name>
<name><surname>Yoder</surname><given-names>J. A.</given-names></name>
<name><surname>Hsieh</surname><given-names>C. L.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Golic</surname><given-names>K. G.</given-names></name>
<name><surname>Jacobsen</surname><given-names>S. E.</given-names></name>
<name><surname>Bestor</surname><given-names>T. H.</given-names></name>
</person-group> <article-title>Methylation of tRNAAsp by the DNA Methyltransferase Homolog Dnmt2</article-title>. <source>Science</source> <year>2006</year>, <volume>311</volume>, <fpage>395</fpage>–<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr31-1087057111421212">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schaefer</surname><given-names>M.</given-names></name>
<name><surname>Lyko</surname><given-names>F.</given-names></name>
</person-group> <article-title>Solving the Dnmt2 Enigma</article-title>. <source>Chromosoma</source> <year>2010</year>, <volume>119</volume>, <fpage>35</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr32-1087057111421212">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okano</surname><given-names>M.</given-names></name>
<name><surname>Bell</surname><given-names>D. W.</given-names></name>
<name><surname>Haber</surname><given-names>D. A.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
</person-group> <article-title>DNA methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development</article-title>. <source>Cell</source> <year>1999</year>, <volume>99</volume>, <fpage>247</fpage>–<lpage>257</lpage>.</citation>
</ref>
<ref id="bibr33-1087057111421212">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gowher</surname><given-names>H.</given-names></name>
<name><surname>Jeltsch</surname><given-names>A.</given-names></name>
</person-group> <article-title>Molecular Enzymology of the Catalytic Domains of the Dnmt3a and Dnmt3b DNA Methyltransferases</article-title>. <source>J. Biol. Chem</source>. <year>2002</year>, <volume>277</volume>, <fpage>20409</fpage>–<lpage>20414</lpage>.</citation>
</ref>
<ref id="bibr34-1087057111421212">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goll</surname><given-names>M. G.</given-names></name>
<name><surname>Bestor</surname><given-names>T. H.</given-names></name>
</person-group> <article-title>Eukaryotic Cytosine Methyltransferases</article-title>. <source>Annu. Rev. Biochem</source>. <year>2005</year>, <volume>74</volume>, <fpage>481</fpage>–<lpage>514</lpage>.</citation>
</ref>
<ref id="bibr35-1087057111421212">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rhee</surname><given-names>I.</given-names></name>
<name><surname>Bachman</surname><given-names>K. E.</given-names></name>
<name><surname>Park</surname><given-names>B. H.</given-names></name>
<name><surname>Jair</surname><given-names>K. W.</given-names></name>
<name><surname>Yen</surname><given-names>R. W.</given-names></name>
<name><surname>Schuebel</surname><given-names>K. E.</given-names></name>
<name><surname>Cui</surname><given-names>H.</given-names></name>
<name><surname>Feinberg</surname><given-names>A. P.</given-names></name>
<name><surname>Lengauer</surname><given-names>C.</given-names></name>
<name><surname>Kinzler</surname><given-names>K. W.</given-names></name><etal/>
</person-group>. <article-title>DNMT1 and DNMT3b Cooperate to Silence Genes in Human Cancer Cells</article-title>. <source>Nature</source> <year>2002</year>, <volume>416</volume>, <fpage>552</fpage>–<lpage>526</lpage>.</citation>
</ref>
<ref id="bibr36-1087057111421212">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liang</surname><given-names>G.</given-names></name>
<name><surname>Chan</surname><given-names>M. F.</given-names></name>
<name><surname>Tomigahara</surname><given-names>Y.</given-names></name>
<name><surname>Tsai</surname><given-names>Y. C.</given-names></name>
<name><surname>Gonzales</surname><given-names>F. A.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
<name><surname>Laird</surname><given-names>P. W.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>Cooperativity between DNA Methyltransferases in the Maintenance Methylation of Repetitive Elements</article-title>. <source>Mol. Cell Biol</source>. <year>2002</year>, <volume>22</volume>, <fpage>480</fpage>–<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr37-1087057111421212">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>T.</given-names></name>
<name><surname>Ueda</surname><given-names>Y.</given-names></name>
<name><surname>Dodge</surname><given-names>J. E.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
</person-group> <article-title>Establishment and Maintenance of Genomic Methylation Patterns in Mouse Embryonic Stem Cells by Dnmt3a and Dnmt3b</article-title>. <source>Mol. Cell Biol</source>. <year>2003</year>, <volume>23</volume>, <fpage>5594</fpage>–<lpage>5605</lpage>.</citation>
</ref>
<ref id="bibr38-1087057111421212">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaneda</surname><given-names>M.</given-names></name>
<name><surname>Okano</surname><given-names>M.</given-names></name>
<name><surname>Hata</surname><given-names>K.</given-names></name>
<name><surname>Sado</surname><given-names>T.</given-names></name>
<name><surname>Tsujimoto</surname><given-names>N.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
<name><surname>Sasaki</surname><given-names>H.</given-names></name>
</person-group> <article-title>Essential Role for De Novo DNA Methyltransferase Dnmt3a in Paternal and Maternal Imprinting</article-title>. <source>Nature</source> <year>2004</year>, <volume>429</volume>, <fpage>900</fpage>–<lpage>903</lpage>.</citation>
</ref>
<ref id="bibr39-1087057111421212">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bourc’his</surname><given-names>D.</given-names></name>
<name><surname>Xu</surname><given-names>G. L.</given-names></name>
<name><surname>Lin</surname><given-names>C. S.</given-names></name>
<name><surname>Bollman</surname><given-names>B.</given-names></name>
<name><surname>Bestor</surname><given-names>T. H.</given-names></name>
</person-group> <article-title>Dnmt3L and the Establishment of Maternal Genomic Imprints</article-title>. <source>Science</source> <year>2001</year>, <volume>294</volume>, <fpage>2536</fpage>–<lpage>2539</lpage>.</citation>
</ref>
<ref id="bibr40-1087057111421212">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bourc’his</surname><given-names>D.</given-names></name>
<name><surname>Bestor</surname><given-names>T. H.</given-names></name>
</person-group> <article-title>Meiotic Catastrophe and Retrotransposon Reactivation in Male Germ Cells Lacking Dnmt3L</article-title>. <source>Nature</source> <year>2004</year>, <volume>431</volume>, <fpage>96</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr41-1087057111421212">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hata</surname><given-names>K.</given-names></name>
<name><surname>Okano</surname><given-names>M.</given-names></name>
<name><surname>Lei</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
</person-group> <article-title>Dnmt3L Cooperates with the Dnmt3 Family of De Novo DNA Methyltransferases to Establish Maternal Imprints in Mice</article-title>. <source>Development</source> <year>2002</year>, <volume>129</volume>, <fpage>1983</fpage>–<lpage>1993</lpage>.</citation>
</ref>
<ref id="bibr42-1087057111421212">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gowher</surname><given-names>H.</given-names></name>
<name><surname>Liebert</surname><given-names>K.</given-names></name>
<name><surname>Hermann</surname><given-names>A.</given-names></name>
<name><surname>Xu</surname><given-names>G.</given-names></name>
<name><surname>Jeltsch</surname><given-names>A.</given-names></name>
</person-group> <article-title>Mechanism of Stimulation of Catalytic Activity of Dnmt3A and Dnmt3B DNA-(Cytosine-C5)-Methyltransferases by Dnmt3L</article-title>. <source>J. Biol. Chem</source>. <year>2005</year>, <volume>280</volume>, <fpage>13341</fpage>–<lpage>13348</lpage>.</citation>
</ref>
<ref id="bibr43-1087057111421212">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jia</surname><given-names>D.</given-names></name>
<name><surname>Jurkowska</surname><given-names>R. Z.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Jeltsch</surname><given-names>A.</given-names></name>
<name><surname>Cheng</surname><given-names>X.</given-names></name>
</person-group> <article-title>Structure of Dnmt3a Bound to Dnmt3L Suggests a Model for De Novo DNA Methylation</article-title>. <source>Nature</source> <year>2007</year>, <volume>449</volume>, <fpage>248</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr44-1087057111421212">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klein</surname><given-names>C. J.</given-names></name>
<name><surname>Botuyan</surname><given-names>M. V.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Ward</surname><given-names>C. J.</given-names></name>
<name><surname>Nicholson</surname><given-names>G. A.</given-names></name>
<name><surname>Hammans</surname><given-names>S.</given-names></name>
<name><surname>Hojo</surname><given-names>K.</given-names></name>
<name><surname>Yamanishi</surname><given-names>H.</given-names></name>
<name><surname>Karpf</surname><given-names>A. R.</given-names></name>
<name><surname>Wallace</surname><given-names>D. C.</given-names></name><etal/>
</person-group>. <article-title>Mutations in DNMT1 Cause Hereditary Sensory Neuropathy with Dementia and Hearing Loss</article-title>. <source>Nat Genet</source> <year>2011</year>, <volume>43</volume>, <fpage>595</fpage>–<lpage>600</lpage>.</citation>
</ref>
<ref id="bibr45-1087057111421212">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Margot</surname><given-names>J. B.</given-names></name>
<name><surname>Aguirre-Arteta</surname><given-names>A. M.</given-names></name>
<name><surname>Di Giacco</surname><given-names>B. V.</given-names></name>
<name><surname>Pradhan</surname><given-names>S.</given-names></name>
<name><surname>Roberts</surname><given-names>R. J.</given-names></name>
<name><surname>Cardoso</surname><given-names>M. C.</given-names></name>
<name><surname>Leonhardt</surname><given-names>H.</given-names></name>
</person-group> <article-title>Structure and Function of the Mouse DNA Methyltransferase Gene: Dnmt1 Shows a Tripartite Structure</article-title>. <source>J. Mol. Biol</source>. <year>2000</year>, <volume>297</volume>, <fpage>293</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr46-1087057111421212">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>G. L.</given-names></name>
<name><surname>Bestor</surname><given-names>T. H.</given-names></name>
<name><surname>Bourc’his</surname><given-names>D.</given-names></name>
<name><surname>Hsieh</surname><given-names>C. L.</given-names></name>
<name><surname>Tommerup</surname><given-names>N.</given-names></name>
<name><surname>Bugge</surname><given-names>M.</given-names></name>
<name><surname>Hulten</surname><given-names>M.</given-names></name>
<name><surname>Qu</surname><given-names>X.</given-names></name>
<name><surname>Russo</surname><given-names>J. J.</given-names></name>
<name><surname>Viegas-Pequignot</surname><given-names>E.</given-names></name>
</person-group> <article-title>Chromosome Instability and Immunodeficiency Syndrome Caused by Mutations in a DNA Methyltransferase Gene</article-title>. <source>Nature</source> <year>1999</year>, <volume>402</volume>, <fpage>187</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr47-1087057111421212">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ehrlich</surname><given-names>M.</given-names></name>
<name><surname>Sanchez</surname><given-names>C.</given-names></name>
<name><surname>Shao</surname><given-names>C.</given-names></name>
<name><surname>Nishiyama</surname><given-names>R.</given-names></name>
<name><surname>Kehrl</surname><given-names>J.</given-names></name>
<name><surname>Kuick</surname><given-names>R.</given-names></name>
<name><surname>Kubota</surname><given-names>T.</given-names></name>
<name><surname>Hanash</surname><given-names>S. M.</given-names></name>
</person-group> <article-title>ICF, an Immunodeficiency Syndrome: DNA Methyltransferase 3B Involvement, Chromosome Anomalies, and Gene Dysregulation</article-title>. <source>Autoimmunity</source> <year>2008</year>, <volume>41</volume>, <fpage>253</fpage>–<lpage>271</lpage>.</citation>
</ref>
<ref id="bibr48-1087057111421212">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Narayan</surname><given-names>A.</given-names></name>
<name><surname>Tuck-Muller</surname><given-names>C.</given-names></name>
<name><surname>Weissbecker</surname><given-names>K.</given-names></name>
<name><surname>Smeets</surname><given-names>D.</given-names></name>
<name><surname>Ehrlich</surname><given-names>M.</given-names></name>
</person-group> <article-title>Hypersensitivity to Radiation-Induced Non-Apoptotic and Apoptotic Death in Cell Lines from Patients with the ICF Chromosome Instability Syndrome</article-title>. <source>Mutat. Res</source>. <year>2000</year>, <volume>456</volume>, <fpage>1</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr49-1087057111421212">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walter</surname><given-names>M. J.</given-names></name>
<name><surname>Ding</surname><given-names>L.</given-names></name>
<name><surname>Shen</surname><given-names>D.</given-names></name>
<name><surname>Shao</surname><given-names>J.</given-names></name>
<name><surname>Grillot</surname><given-names>M.</given-names></name>
<name><surname>McLellan</surname><given-names>M.</given-names></name>
<name><surname>Fulton</surname><given-names>R.</given-names></name>
<name><surname>Schmidt</surname><given-names>H.</given-names></name>
<name><surname>Kalicki-Veizer</surname><given-names>J.</given-names></name>
<name><surname>O’Laughlin</surname><given-names>M.</given-names></name><etal/>
</person-group>. <article-title>Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes</article-title>. <source>Leukemia</source> <year>2011</year>, <volume>25</volume>, <fpage>1153</fpage>–<lpage>1158</lpage>.</citation>
</ref>
<ref id="bibr50-1087057111421212">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ley</surname><given-names>T. J.</given-names></name>
<name><surname>Ding</surname><given-names>L.</given-names></name>
<name><surname>Walter</surname><given-names>M. J.</given-names></name>
<name><surname>McLellan</surname><given-names>M. D.</given-names></name>
<name><surname>Lamprecht</surname><given-names>T.</given-names></name>
<name><surname>Larson</surname><given-names>D. E.</given-names></name>
<name><surname>Kandoth</surname><given-names>C.</given-names></name>
<name><surname>Payton</surname><given-names>J. E.</given-names></name>
<name><surname>Baty</surname><given-names>J.</given-names></name>
<name><surname>Welch</surname><given-names>J.</given-names></name><etal/>
</person-group>. <article-title>DNMT3A Mutations in Acute Myeloid Leukemia</article-title>. <source>N. Engl. J. Med</source>. <year>2010</year>, <volume>363</volume>, <fpage>2424</fpage>–<lpage>2433</lpage>.</citation>
</ref>
<ref id="bibr51-1087057111421212">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yan</surname><given-names>X. J.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Gu</surname><given-names>Z. H.</given-names></name>
<name><surname>Pan</surname><given-names>C. M.</given-names></name>
<name><surname>Lu</surname><given-names>G.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Shi</surname><given-names>J. Y.</given-names></name>
<name><surname>Zhu</surname><given-names>Y. M.</given-names></name>
<name><surname>Tang</surname><given-names>L.</given-names></name><etal/>
</person-group>. <article-title>Exome Sequencing Identifies Somatic Mutations of DNA Methyltransferase Gene DNMT3A in Acute Monocytic Leukemia</article-title>. <source>Nat. Genet</source>. <year>2011</year>, <volume>43</volume>, <fpage>309</fpage>–<lpage>315</lpage>.</citation>
</ref>
<ref id="bibr52-1087057111421212">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eklund</surname><given-names>E. A.</given-names></name>
</person-group> <article-title>The Role of HOX Genes in Malignant Myeloid Disease</article-title>. <source>Curr. Opin. Hematol</source>. <year>2007</year>, <volume>14</volume>, <fpage>85</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr53-1087057111421212">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shah</surname><given-names>N.</given-names></name>
<name><surname>Sukumar</surname><given-names>S.</given-names></name>
</person-group> <article-title>The Hox Genes and Their Roles in Oncogenesis</article-title>. <source>Nat. Rev. Cancer</source> <year>2010</year>, <volume>10</volume>, <fpage>361</fpage>–<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr54-1087057111421212">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feinberg</surname><given-names>A. P.</given-names></name>
<name><surname>Vogelstein</surname><given-names>B.</given-names></name>
</person-group> <article-title>Hypomethylation Distinguishes Genes of Some Human Cancers from Their Normal Counterparts</article-title>. <source>Nature</source> <year>1983</year>, <volume>301</volume>, <fpage>89</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr55-1087057111421212">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riggs</surname><given-names>A. D.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>5-Methylcytosine, Gene Regulation, and Cancer</article-title>. <source>Adv. Cancer Res</source>. <year>1983</year>, <volume>40</volume>, <fpage>1</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr56-1087057111421212">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>C. N.</given-names></name>
<name><surname>Goel</surname><given-names>A.</given-names></name>
<name><surname>Niedzwiecki</surname><given-names>D.</given-names></name>
<name><surname>Dowell</surname><given-names>J. M.</given-names></name>
<name><surname>Wasserman</surname><given-names>L.</given-names></name>
<name><surname>Compton</surname><given-names>C.</given-names></name>
<name><surname>Mayer</surname><given-names>R. J.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>M. M.</given-names></name>
<name><surname>Boland</surname><given-names>C. R.</given-names></name>
</person-group> <article-title>APC Promoter Hypermethylation Contributes to the Loss of APC Expression in Colorectal Cancers with Allelic Loss on 5q</article-title>. <source>Cancer Biol. Ther</source>. <year>2004</year>, <volume>3</volume>, <fpage>960</fpage>–<lpage>964</lpage>.</citation>
</ref>
<ref id="bibr57-1087057111421212">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Rocken</surname><given-names>C.</given-names></name>
<name><surname>Lofton-Day</surname><given-names>C.</given-names></name>
<name><surname>Schulz</surname><given-names>H. U.</given-names></name>
<name><surname>Muller</surname><given-names>O.</given-names></name>
<name><surname>Kutzner</surname><given-names>N.</given-names></name>
<name><surname>Malfertheiner</surname><given-names>P.</given-names></name>
<name><surname>Ebert</surname><given-names>M. P.</given-names></name>
</person-group> <article-title>Molecular Analysis of APC Promoter Methylation and Protein Expression in Colorectal Cancer Metastasis</article-title>. <source>Carcinogenesis</source> <year>2005</year>, <volume>26</volume>, <fpage>37</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr58-1087057111421212">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Virmani</surname><given-names>A. K.</given-names></name>
<name><surname>Rathi</surname><given-names>A.</given-names></name>
<name><surname>Sathyanarayana</surname><given-names>U. G.</given-names></name>
<name><surname>Padar</surname><given-names>A.</given-names></name>
<name><surname>Huang</surname><given-names>C. X.</given-names></name>
<name><surname>Cunnigham</surname><given-names>H. T.</given-names></name>
<name><surname>Farinas</surname><given-names>A. J.</given-names></name>
<name><surname>Milchgrub</surname><given-names>S.</given-names></name>
<name><surname>Euhus</surname><given-names>D. M.</given-names></name>
<name><surname>Gilcrease</surname><given-names>M.</given-names></name><etal/>
</person-group>. <article-title>Aberrant Methylation of the Adenomatous Polyposis Coli (APC) Gene Promoter 1A in Breast and Lung Carcinomas</article-title>. <source>Clin. Cancer Res</source>. <year>2001</year>, <volume>7</volume>, <fpage>1998</fpage>–<lpage>2004</lpage>.</citation>
</ref>
<ref id="bibr59-1087057111421212">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esteller</surname><given-names>M.</given-names></name>
<name><surname>Corn</surname><given-names>P. G.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
<name><surname>Herman</surname><given-names>J. G.</given-names></name>
</person-group> <article-title>A Gene Hypermethylation Profile of Human Cancer</article-title>. <source>Cancer Res</source>. <year>2001</year>, <volume>61</volume>, <fpage>3225</fpage>–<lpage>3229</lpage>.</citation>
</ref>
<ref id="bibr60-1087057111421212">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dobrovic</surname><given-names>A.</given-names></name>
<name><surname>Simpfendorfer</surname><given-names>D.</given-names></name>
</person-group> <article-title>Methylation of the BRCA1 Gene in Sporadic Breast Cancer</article-title>. <source>Cancer Res</source>. <year>1997</year>, <volume>57</volume>, <fpage>3347</fpage>–<lpage>3350</lpage>.</citation>
</ref>
<ref id="bibr61-1087057111421212">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esteller</surname><given-names>M.</given-names></name>
<name><surname>Silva</surname><given-names>J. M.</given-names></name>
<name><surname>Dominguez</surname><given-names>G.</given-names></name>
<name><surname>Bonilla</surname><given-names>F.</given-names></name>
<name><surname>Matias-Guiu</surname><given-names>X.</given-names></name>
<name><surname>Lerma</surname><given-names>E.</given-names></name>
<name><surname>Bussaglia</surname><given-names>E.</given-names></name>
<name><surname>Prat</surname><given-names>J.</given-names></name>
<name><surname>Harkes</surname><given-names>I. C.</given-names></name>
<name><surname>Repasky</surname><given-names>E. A.</given-names></name><etal/>
</person-group>. <article-title>Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors</article-title>. <source>J. Natl. Cancer Inst</source>. <year>2000</year>, <volume>92</volume>, <fpage>564</fpage>–<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr62-1087057111421212">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turner</surname><given-names>N. C.</given-names></name>
<name><surname>Reis-Filho</surname><given-names>J. S.</given-names></name>
<name><surname>Russell</surname><given-names>A. M.</given-names></name>
<name><surname>Springall</surname><given-names>R. J.</given-names></name>
<name><surname>Ryder</surname><given-names>K.</given-names></name>
<name><surname>Steele</surname><given-names>D.</given-names></name>
<name><surname>Savage</surname><given-names>K.</given-names></name>
<name><surname>Gillett</surname><given-names>C. E.</given-names></name>
<name><surname>Schmitt</surname><given-names>F. C.</given-names></name>
<name><surname>Ashworth</surname><given-names>A.</given-names></name><etal/>
</person-group>. <article-title>BRCA1 Dysfunction in Sporadic Basal-Like Breast Cancer</article-title>. <source>Oncogene</source> <year>2007</year>, <volume>26</volume>, <fpage>2126</fpage>–<lpage>2132</lpage>.</citation>
</ref>
<ref id="bibr63-1087057111421212">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herman</surname><given-names>J. G.</given-names></name>
<name><surname>Merlo</surname><given-names>A.</given-names></name>
<name><surname>Mao</surname><given-names>L.</given-names></name>
<name><surname>Lapidus</surname><given-names>R. G.</given-names></name>
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
<name><surname>Davidson</surname><given-names>N. E.</given-names></name>
<name><surname>Sidransky</surname><given-names>D.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
</person-group> <article-title>Inactivation of the CDKN2/p16/MTS1 Gene Is Frequently Associated with Aberrant DNA Methylation in All Common Human Cancers</article-title>. <source>Cancer Res</source>. <year>1995</year>, <volume>55</volume>, <fpage>4525</fpage>–<lpage>4530</lpage>.</citation>
</ref>
<ref id="bibr64-1087057111421212">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esteller</surname><given-names>M.</given-names></name>
<name><surname>Fraga</surname><given-names>M. F.</given-names></name>
<name><surname>Guo</surname><given-names>M.</given-names></name>
<name><surname>Garcia-Foncillas</surname><given-names>J.</given-names></name>
<name><surname>Hedenfalk</surname><given-names>I.</given-names></name>
<name><surname>Godwin</surname><given-names>A. K.</given-names></name>
<name><surname>Trojan</surname><given-names>J.</given-names></name>
<name><surname>Vaurs-Barriere</surname><given-names>C.</given-names></name>
<name><surname>Bignon</surname><given-names>Y. J.</given-names></name>
<name><surname>Ramus</surname><given-names>S.</given-names></name><etal/>
</person-group>. <article-title>DNA Methylation Patterns in Hereditary Human Cancers Mimic Sporadic Tumorigenesis</article-title>. <source>Hum. Mol. Genet</source>. <year>2001</year>, <volume>10</volume>, <fpage>3001</fpage>–<lpage>3007</lpage>.</citation>
</ref>
<ref id="bibr65-1087057111421212">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toyooka</surname><given-names>S.</given-names></name>
<name><surname>Toyooka</surname><given-names>K. O.</given-names></name>
<name><surname>Maruyama</surname><given-names>R.</given-names></name>
<name><surname>Virmani</surname><given-names>A. K.</given-names></name>
<name><surname>Girard</surname><given-names>L.</given-names></name>
<name><surname>Miyajima</surname><given-names>K.</given-names></name>
<name><surname>Harada</surname><given-names>K.</given-names></name>
<name><surname>Ariyoshi</surname><given-names>Y.</given-names></name>
<name><surname>Takahashi</surname><given-names>T.</given-names></name>
<name><surname>Sugio</surname><given-names>K.</given-names></name><etal/>
</person-group>. <article-title>DNA Methylation Profiles of Lung Tumors</article-title>. <source>Mol. Cancer Ther</source>. <year>2001</year>, <volume>1</volume>, <fpage>61</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr66-1087057111421212">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosas</surname><given-names>S. L.</given-names></name>
<name><surname>Koch</surname><given-names>W.</given-names></name>
<name><surname>da Costa Carvalho</surname><given-names>M. G.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
<name><surname>Califano</surname><given-names>J.</given-names></name>
<name><surname>Westra</surname><given-names>W.</given-names></name>
<name><surname>Jen</surname><given-names>J.</given-names></name>
<name><surname>Sidransky</surname><given-names>D.</given-names></name>
</person-group> <article-title>Promoter Hypermethylation Patterns of p16, O6-Methylguanine-DNA-Methyltransferase, and Death-Associated Protein Kinase in Tumors and Saliva of Head and Neck Cancer Patients</article-title>. <source>Cancer Res</source>. <year>2001</year>, <volume>61</volume>, <fpage>939</fpage>–<lpage>942</lpage>.</citation>
</ref>
<ref id="bibr67-1087057111421212">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanchez-Cespedes</surname><given-names>M.</given-names></name>
<name><surname>Esteller</surname><given-names>M.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
<name><surname>Nawroz-Danish</surname><given-names>H.</given-names></name>
<name><surname>Yoo</surname><given-names>G. H.</given-names></name>
<name><surname>Koch</surname><given-names>W. M.</given-names></name>
<name><surname>Jen</surname><given-names>J.</given-names></name>
<name><surname>Herman</surname><given-names>J. G.</given-names></name>
<name><surname>Sidransky</surname><given-names>D.</given-names></name>
</person-group> <article-title>Gene Promoter Hypermethylation in Tumors and Serum of Head and Neck Cancer Patients</article-title>. <source>Cancer Res</source>. <year>2000</year>, <volume>60</volume>, <fpage>892</fpage>–<lpage>895</lpage>.</citation>
</ref>
<ref id="bibr68-1087057111421212">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herman</surname><given-names>J. G.</given-names></name>
<name><surname>Jen</surname><given-names>J.</given-names></name>
<name><surname>Merlo</surname><given-names>A.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
</person-group> <article-title>Hypermethylation-Associated Inactivation Indicates a Tumor Suppressor Role for p15INK4B</article-title>. <source>Cancer Res</source>. <year>1996</year>, <volume>56</volume>, <fpage>722</fpage>–<lpage>727</lpage>.</citation>
</ref>
<ref id="bibr69-1087057111421212">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Batova</surname><given-names>A.</given-names></name>
<name><surname>Diccianni</surname><given-names>M. B.</given-names></name>
<name><surname>Yu</surname><given-names>J. C.</given-names></name>
<name><surname>Nobori</surname><given-names>T.</given-names></name>
<name><surname>Link</surname><given-names>M. P.</given-names></name>
<name><surname>Pullen</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>A. L.</given-names></name>
</person-group> <article-title>Frequent and Selective Methylation of p15 and Deletion of Both p15 and p16 in T-Cell Acute Lymphoblastic Leukemia</article-title>. <source>Cancer Res</source>. <year>1997</year>, <volume>57</volume>, <fpage>832</fpage>–<lpage>836</lpage>.</citation>
</ref>
<ref id="bibr70-1087057111421212">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Graff</surname><given-names>J. R.</given-names></name>
<name><surname>Herman</surname><given-names>J. G.</given-names></name>
<name><surname>Lapidus</surname><given-names>R. G.</given-names></name>
<name><surname>Chopra</surname><given-names>H.</given-names></name>
<name><surname>Xu</surname><given-names>R.</given-names></name>
<name><surname>Jarrard</surname><given-names>D. F.</given-names></name>
<name><surname>Isaacs</surname><given-names>W. B.</given-names></name>
<name><surname>Pitha</surname><given-names>P. M.</given-names></name>
<name><surname>Davidson</surname><given-names>N. E.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
</person-group> <article-title>E-Cadherin Expression Is Silenced by DNA hypermethylation in Human Breast and Prostate Carcinomas</article-title>. <source>Cancer Res</source>. <year>1995</year>, <volume>55</volume>, <fpage>5195</fpage>–<lpage>5199</lpage>.</citation>
</ref>
<ref id="bibr71-1087057111421212">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Graff</surname><given-names>J. R.</given-names></name>
<name><surname>Greenberg</surname><given-names>V. E.</given-names></name>
<name><surname>Herman</surname><given-names>J. G.</given-names></name>
<name><surname>Westra</surname><given-names>W. H.</given-names></name>
<name><surname>Boghaert</surname><given-names>E. R.</given-names></name>
<name><surname>Ain</surname><given-names>K. B.</given-names></name>
<name><surname>Saji</surname><given-names>M.</given-names></name>
<name><surname>Zeiger</surname><given-names>M. A.</given-names></name>
<name><surname>Zimmer</surname><given-names>S. G.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
</person-group> <article-title>Distinct Patterns of E-Cadherin CpG Island Methylation in Papillary, Follicular, Hurthle’s Cell, and Poorly Differentiated Human Thyroid Carcinoma</article-title>. <source>Cancer Res</source>. <year>1998</year>, <volume>58</volume>, <fpage>2063</fpage>–<lpage>2066</lpage>.</citation>
</ref>
<ref id="bibr72-1087057111421212">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lapidus</surname><given-names>R. G.</given-names></name>
<name><surname>Ferguson</surname><given-names>A. T.</given-names></name>
<name><surname>Ottaviano</surname><given-names>Y. L.</given-names></name>
<name><surname>Parl</surname><given-names>F. F.</given-names></name>
<name><surname>Smith</surname><given-names>H. S.</given-names></name>
<name><surname>Weitzman</surname><given-names>S. A.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
<name><surname>Davidson</surname><given-names>N. E.</given-names></name>
</person-group> <article-title>Methylation of Estrogen and Progesterone Receptor Gene 5′ CpG Islands Correlates with Lack of Estrogen and Progesterone Receptor Gene Expression in Breast Tumors</article-title>. <source>Clin. Cancer Res</source>. <year>1996</year>, <volume>2</volume>, <fpage>805</fpage>–<lpage>810</lpage>.</citation>
</ref>
<ref id="bibr73-1087057111421212">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ottaviano</surname><given-names>Y. L.</given-names></name>
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
<name><surname>Parl</surname><given-names>F. F.</given-names></name>
<name><surname>Smith</surname><given-names>H. S.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
<name><surname>Davidson</surname><given-names>N. E.</given-names></name>
</person-group> <article-title>Methylation of the Estrogen Receptor Gene CpG Island Marks Loss of Estrogen Receptor Expression in Human Breast Cancer Cells</article-title>. <source>Cancer Res</source>. <year>1994</year>, <volume>54</volume>, <fpage>2552</fpage>–<lpage>2555</lpage>.</citation>
</ref>
<ref id="bibr74-1087057111421212">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
<name><surname>Belinsky</surname><given-names>S. A.</given-names></name>
</person-group> <article-title>Methylation of the Estrogen Receptor CpG Island in Lung Tumors Is Related to the Specific Type of Carcinogen Exposure</article-title>. <source>Cancer Res</source>. <year>1996</year>, <volume>56</volume>, <fpage>3655</fpage>–<lpage>3658</lpage>.</citation>
</ref>
<ref id="bibr75-1087057111421212">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
<name><surname>Zehnbauer</surname><given-names>B. A.</given-names></name>
<name><surname>Civin</surname><given-names>C. I.</given-names></name>
<name><surname>Collector</surname><given-names>M. I.</given-names></name>
<name><surname>Sharkis</surname><given-names>S. J.</given-names></name>
<name><surname>Davidson</surname><given-names>N. E.</given-names></name>
<name><surname>Kaufmann</surname><given-names>S. H.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
</person-group> <article-title>The Estrogen Receptor CpG Island Is Methylated in Most Hematopoietic Neoplasms</article-title>. <source>Cancer Res</source>. <year>1996</year>, <volume>56</volume>, <fpage>973</fpage>–<lpage>977</lpage>.</citation>
</ref>
<ref id="bibr76-1087057111421212">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yan</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Davidson</surname><given-names>N. E.</given-names></name>
</person-group> <article-title>Role of DNA Methylation and Histone Acetylation in Steroid Receptor Expression in Breast Cancer</article-title>. <source>J. Mammary Gland Biol. Neoplasia</source> <year>2001</year>, <volume>6</volume>, <fpage>183</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr77-1087057111421212">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>L. C.</given-names></name>
<name><surname>Chui</surname><given-names>R.</given-names></name>
<name><surname>Nakajima</surname><given-names>K.</given-names></name>
<name><surname>Oh</surname><given-names>B. R.</given-names></name>
<name><surname>Au</surname><given-names>H. C.</given-names></name>
<name><surname>Dahiya</surname><given-names>R.</given-names></name>
</person-group> <article-title>Frequent Methylation of Estrogen Receptor in Prostate Cancer: Correlation with Tumor Progression</article-title>. <source>Cancer Res</source>. <year>2000</year>, <volume>60</volume>, <fpage>702</fpage>–<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr78-1087057111421212">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Samowitz</surname><given-names>W. S.</given-names></name>
<name><surname>Albertsen</surname><given-names>H.</given-names></name>
<name><surname>Herrick</surname><given-names>J.</given-names></name>
<name><surname>Levin</surname><given-names>T. R.</given-names></name>
<name><surname>Sweeney</surname><given-names>C.</given-names></name>
<name><surname>Murtaugh</surname><given-names>M. A.</given-names></name>
<name><surname>Wolff</surname><given-names>R. K.</given-names></name>
<name><surname>Slattery</surname><given-names>M. L.</given-names></name>
</person-group> <article-title>Evaluation of a Large, Population-Based Sample Supports a CpG Island Methylator Phenotype in Colon Cancer</article-title>. <source>Gastroenterology</source> <year>2005</year>, <volume>129</volume>, <fpage>837</fpage>–<lpage>845</lpage>.</citation>
</ref>
<ref id="bibr79-1087057111421212">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>Y.</given-names></name>
<name><surname>Ueda</surname><given-names>H.</given-names></name>
<name><surname>Etoh</surname><given-names>T.</given-names></name>
<name><surname>Koike</surname><given-names>E.</given-names></name>
<name><surname>Fujinami</surname><given-names>N.</given-names></name>
<name><surname>Mitsuhashi</surname><given-names>A.</given-names></name>
<name><surname>Hoshiai</surname><given-names>H.</given-names></name>
</person-group> <article-title>A Change in Promoter Methylation of hMLH1 Is a Cause of Acquired Resistance to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer</article-title>. <source>Anticancer Res</source>. <year>2007</year>, <volume>27</volume>, <fpage>1449</fpage>–<lpage>1452</lpage>.</citation>
</ref>
<ref id="bibr80-1087057111421212">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herman</surname><given-names>J. G.</given-names></name>
<name><surname>Umar</surname><given-names>A.</given-names></name>
<name><surname>Polyak</surname><given-names>K.</given-names></name>
<name><surname>Graff</surname><given-names>J. R.</given-names></name>
<name><surname>Ahuja</surname><given-names>N.</given-names></name>
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
<name><surname>Markowitz</surname><given-names>S.</given-names></name>
<name><surname>Willson</surname><given-names>J. K.</given-names></name>
<name><surname>Hamilton</surname><given-names>S. R.</given-names></name>
<name><surname>Kinzler</surname><given-names>K. W.</given-names></name><etal/>
</person-group>. <article-title>Incidence and Functional Consequences of hMLH1 Promoter Hypermethylation in Colorectal Carcinoma</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source>. <year>1998</year>, <volume>95</volume>, <fpage>6870</fpage>–<lpage>6875</lpage>.</citation>
</ref>
<ref id="bibr81-1087057111421212">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kane</surname><given-names>M. F.</given-names></name>
<name><surname>Loda</surname><given-names>M.</given-names></name>
<name><surname>Gaida</surname><given-names>G. M.</given-names></name>
<name><surname>Lipman</surname><given-names>J.</given-names></name>
<name><surname>Mishra</surname><given-names>R.</given-names></name>
<name><surname>Goldman</surname><given-names>H.</given-names></name>
<name><surname>Jessup</surname><given-names>J. M.</given-names></name>
<name><surname>Kolodner</surname><given-names>R.</given-names></name>
</person-group> <article-title>Methylation of the hMLH1 Promoter Correlates with Lack of Expression of hMLH1 in Sporadic Colon Tumors and Mismatch Repair-Defective Human Tumor Cell Lines</article-title>. <source>Cancer Res</source>. <year>1997</year>, <volume>57</volume>, <fpage>808</fpage>–<lpage>811</lpage>.</citation>
</ref>
<ref id="bibr82-1087057111421212">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esteller</surname><given-names>M.</given-names></name>
<name><surname>Levine</surname><given-names>R.</given-names></name>
<name><surname>Baylin</surname><given-names>S. B.</given-names></name>
<name><surname>Ellenson</surname><given-names>L. H.</given-names></name>
<name><surname>Herman</surname><given-names>J. G.</given-names></name>
</person-group> <article-title>MLH1 Promoter Hypermethylation Is Associated with the Microsatellite Instability Phenotype in Sporadic Endometrial Carcinomas</article-title>. <source>Oncogene</source> <year>1998</year>, <volume>17</volume>, <fpage>2413</fpage>–<lpage>2417</lpage>.</citation>
</ref>
<ref id="bibr83-1087057111421212">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leung</surname><given-names>S. Y.</given-names></name>
<name><surname>Yuen</surname><given-names>S. T.</given-names></name>
<name><surname>Chung</surname><given-names>L. P.</given-names></name>
<name><surname>Chu</surname><given-names>K. M.</given-names></name>
<name><surname>Chan</surname><given-names>A. S.</given-names></name>
<name><surname>Ho</surname><given-names>J. C.</given-names></name>
</person-group> <article-title>hMLH1 Promoter Methylation and Lack of hMLH1 Expression in Sporadic Gastric Carcinomas with High-Frequency Microsatellite Instability</article-title>. <source>Cancer Res</source>. <year>1999</year>, <volume>59</volume>, <fpage>159</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr84-1087057111421212">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agathanggelou</surname><given-names>A.</given-names></name>
<name><surname>Honorio</surname><given-names>S.</given-names></name>
<name><surname>Macartney</surname><given-names>D. P.</given-names></name>
<name><surname>Martinez</surname><given-names>A.</given-names></name>
<name><surname>Dallol</surname><given-names>A.</given-names></name>
<name><surname>Rader</surname><given-names>J.</given-names></name>
<name><surname>Fullwood</surname><given-names>P.</given-names></name>
<name><surname>Chauhan</surname><given-names>A.</given-names></name>
<name><surname>Walker</surname><given-names>R.</given-names></name>
<name><surname>Shaw</surname><given-names>J. A.</given-names></name><etal/>
</person-group>. <article-title>Methylation Associated Inactivation of RASSF1A from Region 3p21.3 in Lung, Breast and Ovarian Tumours</article-title>. <source>Oncogene</source> <year>2001</year>, <volume>20</volume>, <fpage>1509</fpage>–<lpage>1518</lpage>.</citation>
</ref>
<ref id="bibr85-1087057111421212">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choi</surname><given-names>Y. L.</given-names></name>
<name><surname>Kang</surname><given-names>S. Y.</given-names></name>
<name><surname>Shin</surname><given-names>Y. K.</given-names></name>
<name><surname>Choi</surname><given-names>J. S.</given-names></name>
<name><surname>Kim</surname><given-names>S. H.</given-names></name>
<name><surname>Lee</surname><given-names>S. J.</given-names></name>
<name><surname>Bae</surname><given-names>D. S.</given-names></name>
<name><surname>Ahn</surname><given-names>G.</given-names></name>
</person-group> <article-title>Aberrant Hypermethylation of RASSF1A Promoter in Ovarian Borderline Tumors and Carcinomas</article-title>. <source>Virchows Arch</source> <year>2006</year>, <volume>448</volume>, <fpage>331</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr86-1087057111421212">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greger</surname><given-names>V.</given-names></name>
<name><surname>Debus</surname><given-names>N.</given-names></name>
<name><surname>Lohmann</surname><given-names>D.</given-names></name>
<name><surname>Hopping</surname><given-names>W.</given-names></name>
<name><surname>Passarge</surname><given-names>E.</given-names></name>
<name><surname>Horsthemke</surname><given-names>B.</given-names></name>
</person-group> <article-title>Frequency and Parental Origin of Hypermethylated RB1 Alleles in Retinoblastoma</article-title>. <source>Hum. Genet</source>. <year>1994</year>, <volume>94</volume>, <fpage>491</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr87-1087057111421212">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stirzaker</surname><given-names>C.</given-names></name>
<name><surname>Millar</surname><given-names>D. S.</given-names></name>
<name><surname>Paul</surname><given-names>C. L.</given-names></name>
<name><surname>Warnecke</surname><given-names>P. M.</given-names></name>
<name><surname>Harrison</surname><given-names>J.</given-names></name>
<name><surname>Vincent</surname><given-names>P. C.</given-names></name>
<name><surname>Frommer</surname><given-names>M.</given-names></name>
<name><surname>Clark</surname><given-names>S. J.</given-names></name>
</person-group> <article-title>Extensive DNA Methylation Spanning the Rb Promoter in Retinoblastoma Tumors</article-title>. <source>Cancer Res</source>. <year>1997</year>, <volume>57</volume>, <fpage>2229</fpage>–<lpage>2237</lpage>.</citation>
</ref>
<ref id="bibr88-1087057111421212">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gonzalez-Gomez</surname><given-names>P.</given-names></name>
<name><surname>Bello</surname><given-names>M. J.</given-names></name>
<name><surname>Alonso</surname><given-names>M. E.</given-names></name>
<name><surname>Arjona</surname><given-names>D.</given-names></name>
<name><surname>Lomas</surname><given-names>J.</given-names></name>
<name><surname>de Campos</surname><given-names>J. M.</given-names></name>
<name><surname>Isla</surname><given-names>A.</given-names></name>
<name><surname>Rey</surname><given-names>J. A.</given-names></name>
</person-group> <article-title>CpG Island Methylation Status and Mutation Analysis of the RB1 Gene Essential Promoter Region and Protein-Binding Pocket Domain in Nervous System Tumours</article-title>. <source>Br. J. Cancer</source> <year>2003</year>, <volume>88</volume>, <fpage>109</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr89-1087057111421212">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herman</surname><given-names>J. G.</given-names></name>
<name><surname>Latif</surname><given-names>F.</given-names></name>
<name><surname>Weng</surname><given-names>Y.</given-names></name>
<name><surname>Lerman</surname><given-names>M. I.</given-names></name>
<name><surname>Zbar</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Samid</surname><given-names>D.</given-names></name>
<name><surname>Duan</surname><given-names>D. S.</given-names></name>
<name><surname>Gnarra</surname><given-names>J. R.</given-names></name>
<name><surname>Linehan</surname><given-names>W. M.</given-names></name><etal/>
</person-group>. <article-title>Silencing of the VHL Tumor-Suppressor Gene by DNA Methylation in Renal Carcinoma</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source>. <year>1994</year>, <volume>91</volume>, <fpage>9700</fpage>–<lpage>9704</lpage>.</citation>
</ref>
<ref id="bibr90-1087057111421212">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clifford</surname><given-names>S. C.</given-names></name>
<name><surname>Prowse</surname><given-names>A. H.</given-names></name>
<name><surname>Affara</surname><given-names>N. A.</given-names></name>
<name><surname>Buys</surname><given-names>C. H.</given-names></name>
<name><surname>Maher</surname><given-names>E. R.</given-names></name>
</person-group> <article-title>Inactivation of the von Hippel-Lindau (VHL) Tumour Suppressor Gene and Allelic Losses at Chromosome Arm 3p in Primary Renal Cell Carcinoma: Evidence for a VHL-Independent Pathway in Clear Cell Renal Tumourigenesis</article-title>. <source>Genes Chromosomes Cancer</source> <year>1998</year>, <volume>22</volume>, <fpage>200</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr91-1087057111421212">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurkjian</surname><given-names>C.</given-names></name>
<name><surname>Kummar</surname><given-names>S.</given-names></name>
<name><surname>Murgo</surname><given-names>A. J.</given-names></name>
</person-group> <article-title>DNA Methylation: Its Role in Cancer Development and Therapy</article-title>. <source>Curr. Probl. Cancer</source> <year>2008</year>, <volume>32</volume>, <fpage>187</fpage>–<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr92-1087057111421212">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eads</surname><given-names>C. A.</given-names></name>
<name><surname>Nickel</surname><given-names>A. E.</given-names></name>
<name><surname>Laird</surname><given-names>P. W.</given-names></name>
</person-group> <article-title>Complete Genetic Suppression of Polyp Formation and Reduction of CpG-Island Hypermethylation in Apc(Min/+) Dnmt1-Hypomorphic Mice</article-title>. <source>Cancer Res</source>. <year>2002</year>, <volume>62</volume>, <fpage>1296</fpage>–<lpage>1299</lpage>.</citation>
</ref>
<ref id="bibr93-1087057111421212">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>H.</given-names></name>
<name><surname>Yamada</surname><given-names>Y.</given-names></name>
<name><surname>Nguyen</surname><given-names>S.</given-names></name>
<name><surname>Linhart</surname><given-names>H.</given-names></name>
<name><surname>Jackson-Grusby</surname><given-names>L.</given-names></name>
<name><surname>Meissner</surname><given-names>A.</given-names></name>
<name><surname>Meletis</surname><given-names>K.</given-names></name>
<name><surname>Lo</surname><given-names>G.</given-names></name>
<name><surname>Jaenisch</surname><given-names>R.</given-names></name>
</person-group> <article-title>Suppression of Intestinal Neoplasia by Deletion of Dnmt3b</article-title>. <source>Mol. Cell Biol</source>. <year>2006</year>, <volume>26</volume>, <fpage>2976</fpage>–<lpage>2983</lpage>.</citation>
</ref>
<ref id="bibr94-1087057111421212">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Linhart</surname><given-names>H. G.</given-names></name>
<name><surname>Lin</surname><given-names>H.</given-names></name>
<name><surname>Yamada</surname><given-names>Y.</given-names></name>
<name><surname>Moran</surname><given-names>E.</given-names></name>
<name><surname>Steine</surname><given-names>E. J.</given-names></name>
<name><surname>Gokhale</surname><given-names>S.</given-names></name>
<name><surname>Lo</surname><given-names>G.</given-names></name>
<name><surname>Cantu</surname><given-names>E.</given-names></name>
<name><surname>Ehrich</surname><given-names>M.</given-names></name>
<name><surname>He</surname><given-names>T.</given-names></name><etal/>
</person-group>. <article-title>Dnmt3b Promotes Tumorigenesis In Vivo by Gene-Specific De Novo Methylation and Transcriptional Silencing</article-title>. <source>Genes Dev</source>. <year>2007</year>, <volume>21</volume>, <fpage>3110</fpage>–<lpage>3122</lpage>.</citation>
</ref>
<ref id="bibr95-1087057111421212">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fabbri</surname><given-names>M.</given-names></name>
<name><surname>Calin</surname><given-names>G. A.</given-names></name>
</person-group> <article-title>Epigenetics and miRNAs in Human Cancer</article-title>. <source>Adv. Genet</source>. <year>2010</year>, <volume>70</volume>, <fpage>87</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr96-1087057111421212">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roman-Gomez</surname><given-names>J.</given-names></name>
<name><surname>Agirre</surname><given-names>X.</given-names></name>
<name><surname>Jimenez-Velasco</surname><given-names>A.</given-names></name>
<name><surname>Arqueros</surname><given-names>V.</given-names></name>
<name><surname>Vilas-Zornoza</surname><given-names>A.</given-names></name>
<name><surname>Rodriguez-Otero</surname><given-names>P.</given-names></name>
<name><surname>Martin-Subero</surname><given-names>I.</given-names></name>
<name><surname>Garate</surname><given-names>L.</given-names></name>
<name><surname>Cordeu</surname><given-names>L.</given-names></name>
<name><surname>San Jose-Eneriz</surname><given-names>E.</given-names></name><etal/>
</person-group>. <article-title>Epigenetic Regulation of microRNAs in Acute Lymphoblastic Leukemia</article-title>. <source>J. Clin. Oncol</source>. <year>2009</year>, <volume>27</volume>, <fpage>1316</fpage>–<lpage>1322</lpage>.</citation>
</ref>
<ref id="bibr97-1087057111421212">
<label>97.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agirre</surname><given-names>X.</given-names></name>
<name><surname>Vilas-Zornoza</surname><given-names>A.</given-names></name>
<name><surname>Jimenez-Velasco</surname><given-names>A.</given-names></name>
<name><surname>Martin-Subero</surname><given-names>J. I.</given-names></name>
<name><surname>Cordeu</surname><given-names>L.</given-names></name>
<name><surname>Garate</surname><given-names>L.</given-names></name>
<name><surname>San Jose-Eneriz</surname><given-names>E.</given-names></name>
<name><surname>Abizanda</surname><given-names>G.</given-names></name>
<name><surname>Rodriguez-Otero</surname><given-names>P.</given-names></name>
<name><surname>Fortes</surname><given-names>P.</given-names></name><etal/>
</person-group>. <article-title>Epigenetic Silencing of the Tumor Suppressor microRNA Hsa-miR-124a Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia</article-title>. <source>Cancer Res</source>. <year>2009</year>, <volume>69</volume>, <fpage>4443</fpage>–<lpage>4453</lpage>.</citation>
</ref>
<ref id="bibr98-1087057111421212">
<label>98.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miremadi</surname><given-names>A.</given-names></name>
<name><surname>Oestergaard</surname><given-names>M. Z.</given-names></name>
<name><surname>Pharoah</surname><given-names>P. D.</given-names></name>
<name><surname>Caldas</surname><given-names>C.</given-names></name>
</person-group> <article-title>Cancer Genetics of Epigenetic Genes</article-title>. <source>Hum. Mol. Genet</source>. <year>2007</year>, <volume>16</volume>(Spec No 1), <fpage>R28</fpage>–<lpage>R49</lpage>.</citation>
</ref>
<ref id="bibr99-1087057111421212">
<label>99.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yi</surname><given-names>J. M.</given-names></name>
<name><surname>Tsai</surname><given-names>H. C.</given-names></name>
<name><surname>Glockner</surname><given-names>S. C.</given-names></name>
<name><surname>Lin</surname><given-names>S.</given-names></name>
<name><surname>Ohm</surname><given-names>J. E.</given-names></name>
<name><surname>Easwaran</surname><given-names>H.</given-names></name>
<name><surname>James</surname><given-names>C. D.</given-names></name>
<name><surname>Costello</surname><given-names>J. F.</given-names></name>
<name><surname>Riggins</surname><given-names>G.</given-names></name>
<name><surname>Eberhart</surname><given-names>C. G.</given-names></name><etal/>
</person-group>. <article-title>Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors</article-title>. <source>Cancer Res</source>. <year>2008</year>, <volume>68</volume>, <fpage>8094</fpage>–<lpage>8103</lpage>.</citation>
</ref>
<ref id="bibr100-1087057111421212">
<label>100.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saito</surname><given-names>Y.</given-names></name>
<name><surname>Kanai</surname><given-names>Y.</given-names></name>
<name><surname>Sakamoto</surname><given-names>M.</given-names></name>
<name><surname>Saito</surname><given-names>H.</given-names></name>
<name><surname>Ishii</surname><given-names>H.</given-names></name>
<name><surname>Hirohashi</surname><given-names>S.</given-names></name>
</person-group> <article-title>Overexpression of a Splice Variant of DNA Methyltransferase 3b, DNMT3b4, Associated with DNA Hypomethylation on Pericentromeric Satellite Regions during Human Hepatocarcinogenesis</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source>. <year>2002</year>, <volume>99</volume>, <fpage>10060</fpage>–<lpage>10065</lpage>.</citation>
</ref>
<ref id="bibr101-1087057111421212">
<label>101.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Walsh</surname><given-names>G.</given-names></name>
<name><surname>Liu</surname><given-names>D. D.</given-names></name>
<name><surname>Lee</surname><given-names>J. J.</given-names></name>
<name><surname>Mao</surname><given-names>L.</given-names></name>
</person-group> <article-title>Expression of Delta DNMT3B Variants and Its Association with Promoter Methylation of p16 and RASSF1A in Primary Non-Small Cell Lung Cancer</article-title>. <source>Cancer Res</source>. <year>2006</year>, <volume>66</volume>, <fpage>8361</fpage>–<lpage>8366</lpage>.</citation>
</ref>
<ref id="bibr102-1087057111421212">
<label>102.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>S.</given-names></name>
<name><surname>Rodriguez</surname><given-names>M.</given-names></name>
<name><surname>Yue</surname><given-names>P.</given-names></name>
<name><surname>Jang</surname><given-names>S. J.</given-names></name>
<name><surname>Mao</surname><given-names>L.</given-names></name>
</person-group> <article-title>A Novel DNMT3B Subfamily, DeltaDNMT3B, Is the Predominant Form of DNMT3B in Non-Small Cell Lung Cancer</article-title>. <source>Int. J. Oncol</source>. <year>2006</year>, <volume>29</volume>, <fpage>201</fpage>–<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr103-1087057111421212">
<label>103.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ostler</surname><given-names>K. R.</given-names></name>
<name><surname>Davis</surname><given-names>E. M.</given-names></name>
<name><surname>Payne</surname><given-names>S. L.</given-names></name>
<name><surname>Gosalia</surname><given-names>B. B.</given-names></name>
<name><surname>Exposito-Cespedes</surname><given-names>J.</given-names></name>
<name><surname>Le Beau</surname><given-names>M. M.</given-names></name>
<name><surname>Godley</surname><given-names>L. A.</given-names></name>
</person-group> <article-title>Cancer Cells Express Aberrant DNMT3B Transcripts Encoding Truncated Proteins</article-title>. <source>Oncogene</source> <year>2007</year>, <volume>26</volume>, <fpage>5553</fpage>–<lpage>5563</lpage>.</citation>
</ref>
<ref id="bibr104-1087057111421212">
<label>104.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eden</surname><given-names>A.</given-names></name>
<name><surname>Gaudet</surname><given-names>F.</given-names></name>
<name><surname>Waghmare</surname><given-names>A.</given-names></name>
<name><surname>Jaenisch</surname><given-names>R.</given-names></name>
</person-group> <article-title>Chromosomal Instability and Tumors Promoted by DNA Hypomethylation</article-title>. <source>Science</source> <year>2003</year>, <volume>300</volume>, <fpage>455</fpage>.</citation>
</ref>
<ref id="bibr105-1087057111421212">
<label>105.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gaudet</surname><given-names>F.</given-names></name>
<name><surname>Hodgson</surname><given-names>J. G.</given-names></name>
<name><surname>Eden</surname><given-names>A.</given-names></name>
<name><surname>Jackson-Grusby</surname><given-names>L.</given-names></name>
<name><surname>Dausman</surname><given-names>J.</given-names></name>
<name><surname>Gray</surname><given-names>J. W.</given-names></name>
<name><surname>Leonhardt</surname><given-names>H.</given-names></name>
<name><surname>Jaenisch</surname><given-names>R.</given-names></name>
</person-group> <article-title>Induction of Tumors in Mice by Genomic Hypomethylation</article-title>. <source>Science</source> <year>2003</year>, <volume>300</volume>, <fpage>489</fpage>–<lpage>492</lpage>.</citation>
</ref>
<ref id="bibr106-1087057111421212">
<label>106.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dodge</surname><given-names>J. E.</given-names></name>
<name><surname>Okano</surname><given-names>M.</given-names></name>
<name><surname>Dick</surname><given-names>F.</given-names></name>
<name><surname>Tsujimoto</surname><given-names>N.</given-names></name>
<name><surname>Chen</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Ueda</surname><given-names>Y.</given-names></name>
<name><surname>Dyson</surname><given-names>N.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
</person-group> <article-title>Inactivation of Dnmt3b in Mouse Embryonic Fibroblasts Results in DNA Hypomethylation, Chromosomal Instability, and Spontaneous Immortalization</article-title>. <source>J. Biol. Chem</source>. <year>2005</year>, <volume>280</volume>, <fpage>17986</fpage>–<lpage>17991</lpage>.</citation>
</ref>
<ref id="bibr107-1087057111421212">
<label>107.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>R. Z.</given-names></name>
<name><surname>Pettersson</surname><given-names>U.</given-names></name>
<name><surname>Beard</surname><given-names>C.</given-names></name>
<name><surname>Jackson-Grusby</surname><given-names>L.</given-names></name>
<name><surname>Jaenisch</surname><given-names>R.</given-names></name>
</person-group> <article-title>DNA Hypomethylation Leads to Elevated Mutation Rates</article-title>. <source>Nature</source> <year>1998</year>, <volume>395</volume>, <fpage>89</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr108-1087057111421212">
<label>108.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brown</surname><given-names>K. D.</given-names></name>
<name><surname>Robertson</surname><given-names>K. D.</given-names></name>
</person-group> <article-title>DNMT1 Knockout Delivers a Strong Blow to Genome Stability and Cell Viability</article-title>. <source>Nat. Genet</source>. <year>2007</year>, <volume>39</volume>, <fpage>289</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr109-1087057111421212">
<label>109.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haas</surname><given-names>P. S.</given-names></name>
<name><surname>Wijermans</surname><given-names>P.</given-names></name>
<name><surname>Verhoef</surname><given-names>G.</given-names></name>
<name><surname>Lubbert</surname><given-names>M.</given-names></name>
</person-group> <article-title>Treatment of Myelodysplastic Syndrome with a DNA Methyltransferase Inhibitor: Lack of Evidence for Induction of Chromosomal Instability</article-title>. <source>Leuk. Res</source>. <year>2006</year>, <volume>30</volume>, <fpage>338</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr110-1087057111421212">
<label>110.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liang</surname><given-names>G.</given-names></name>
<name><surname>Gonzales</surname><given-names>F. A.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
<name><surname>Orntoft</surname><given-names>T. F.</given-names></name>
<name><surname>Thykjaer</surname><given-names>T.</given-names></name>
</person-group> <article-title>Analysis of Gene Induction in Human Fibroblasts and Bladder Cancer Cells Exposed to the Methylation Inhibitor 5-aza-2′-deoxycytidine</article-title>. <source>Cancer Res</source>. <year>2002</year>, <volume>62</volume>, <fpage>961</fpage>–<lpage>966</lpage>.</citation>
</ref>
<ref id="bibr111-1087057111421212">
<label>111.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
<name><surname>Kantarjian</surname><given-names>H. M.</given-names></name>
</person-group> <article-title>Targeting DNA Methylation</article-title>. <source>Clin. Cancer Res</source>. <year>2009</year>, <volume>15</volume>, <fpage>3938</fpage>–<lpage>3946</lpage>.</citation>
</ref>
<ref id="bibr112-1087057111421212">
<label>112.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoo</surname><given-names>C. B.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>Epigenetic Therapy of Cancer: Past, Present and Future</article-title>. <source>Nat. Rev. Drug Discov</source>. <year>2006</year>, <volume>5</volume>, <fpage>37</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr113-1087057111421212">
<label>113.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
<name><surname>Taylor</surname><given-names>S. M.</given-names></name>
</person-group> <article-title>Cellular Differentiation, Cytidine Analogs and DNA Methylation</article-title>. <source>Cell</source> <year>1980</year>, <volume>20</volume>, <fpage>85</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr114-1087057111421212">
<label>114.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santi</surname><given-names>D. V.</given-names></name>
<name><surname>Norment</surname><given-names>A.</given-names></name>
<name><surname>Garrett</surname><given-names>C. E.</given-names></name>
</person-group> <article-title>Covalent Bond Formation between a DNA-Cytosine Methyltransferase and DNA Containing 5-Azacytosine</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source>. <year>1984</year>, <volume>81</volume>, <fpage>6993</fpage>–<lpage>6997</lpage>.</citation>
</ref>
<ref id="bibr115-1087057111421212">
<label>115.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghoshal</surname><given-names>K.</given-names></name>
<name><surname>Datta</surname><given-names>J.</given-names></name>
<name><surname>Majumder</surname><given-names>S.</given-names></name>
<name><surname>Bai</surname><given-names>S.</given-names></name>
<name><surname>Kutay</surname><given-names>H.</given-names></name>
<name><surname>Motiwala</surname><given-names>T.</given-names></name>
<name><surname>Jacob</surname><given-names>S. T.</given-names></name>
</person-group> <article-title>5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal</article-title>. <source>Mol. Cell Biol</source>. <year>2005</year>, <volume>25</volume>, <fpage>4727</fpage>–<lpage>4741</lpage>.</citation>
</ref>
<ref id="bibr116-1087057111421212">
<label>116.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qin</surname><given-names>T.</given-names></name>
<name><surname>Youssef</surname><given-names>E. M.</given-names></name>
<name><surname>Jelinek</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
<name><surname>Yang</surname><given-names>A. S.</given-names></name>
<name><surname>Garcia-Manero</surname><given-names>G.</given-names></name>
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
</person-group> <article-title>Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines</article-title>. <source>Clin. Cancer Res</source>. <year>2007</year>, <volume>13</volume>, <fpage>4225</fpage>–<lpage>4232</lpage>.</citation>
</ref>
<ref id="bibr117-1087057111421212">
<label>117.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hollenbach</surname><given-names>P. W.</given-names></name>
<name><surname>Nguyen</surname><given-names>A. N.</given-names></name>
<name><surname>Brady</surname><given-names>H.</given-names></name>
<name><surname>Williams</surname><given-names>M.</given-names></name>
<name><surname>Ning</surname><given-names>Y.</given-names></name>
<name><surname>Richard</surname><given-names>N.</given-names></name>
<name><surname>Krushel</surname><given-names>L.</given-names></name>
<name><surname>Aukerman</surname><given-names>S. L.</given-names></name>
<name><surname>Heise</surname><given-names>C.</given-names></name>
<name><surname>MacBeth</surname><given-names>K. J.</given-names></name>
</person-group> <article-title>A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines</article-title>. <source>PLoS One</source> <year>2010</year>, <volume>5</volume>, <fpage>e9001</fpage>.</citation>
</ref>
<ref id="bibr118-1087057111421212">
<label>118.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stresemann</surname><given-names>C.</given-names></name>
<name><surname>Lyko</surname><given-names>F.</given-names></name>
</person-group> <article-title>Modes of Action of the DNA Methyltransferase Inhibitors Azacytidine and Decitabine</article-title>. <source>Int. J. Cancer</source> <year>2008</year>, <volume>123</volume>, <fpage>8</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr119-1087057111421212">
<label>119.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Velez-Garcia</surname><given-names>E.</given-names></name>
<name><surname>Vogler</surname><given-names>W. R.</given-names></name>
<name><surname>Bartolucci</surname><given-names>A. A.</given-names></name>
<name><surname>Arkun</surname><given-names>S. N.</given-names></name>
</person-group> <article-title>Twice Weekly 5-Azacytidine Infusion in Dissmeinated Metastatic Cancer: A Phase II Study</article-title>. <source>Cancer Treat. Rep</source>. <year>1977</year>, <volume>61</volume>, <fpage>1675</fpage>–<lpage>1677</lpage>.</citation>
</ref>
<ref id="bibr120-1087057111421212">
<label>120.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Srinivasan</surname><given-names>U.</given-names></name>
<name><surname>Reaman</surname><given-names>G. H.</given-names></name>
<name><surname>Poplack</surname><given-names>D. G.</given-names></name>
<name><surname>Glaubiger</surname><given-names>D. L.</given-names></name>
<name><surname>LeVine</surname><given-names>A. S.</given-names></name>
</person-group> <article-title>Phase II Study of 5-Azacytidine in Sarcomas of Bone</article-title>. <source>Am. J. Clin. Oncol</source>. <year>1982</year>,<volume>5</volume>, <fpage>411</fpage>–<lpage>415</lpage>.</citation>
</ref>
<ref id="bibr121-1087057111421212">
<label>121.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Momparler</surname><given-names>R. L.</given-names></name>
<name><surname>Rivard</surname><given-names>G. E.</given-names></name>
<name><surname>Gyger</surname><given-names>M.</given-names></name>
</person-group> <article-title>Clinical Trial on 5-Aza-2′-Deoxycytidine in Patients with Acute Leukemia</article-title>. <source>Pharmacol. Ther</source>. <year>1985</year>, <volume>30</volume>, <fpage>277</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr122-1087057111421212">
<label>122.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silverman</surname><given-names>L. R.</given-names></name>
<name><surname>Demakos</surname><given-names>E. P.</given-names></name>
<name><surname>Peterson</surname><given-names>B. L.</given-names></name>
<name><surname>Kornblith</surname><given-names>A. B.</given-names></name>
<name><surname>Holland</surname><given-names>J. C.</given-names></name>
<name><surname>Odchimar-Reissig</surname><given-names>R.</given-names></name>
<name><surname>Stone</surname><given-names>R. M.</given-names></name>
<name><surname>Nelson</surname><given-names>D.</given-names></name>
<name><surname>Powell</surname><given-names>B. L.</given-names></name>
<name><surname>DeCastro</surname><given-names>C. M.</given-names></name><etal/>
</person-group>. <article-title>Randomized Controlled Trial of Azacitidine in Patients with the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B</article-title>. <source>J. Clin. Oncol</source>. <year>2002</year>, <volume>20</volume>, <fpage>2429</fpage>–<lpage>2440</lpage>.</citation>
</ref>
<ref id="bibr123-1087057111421212">
<label>123.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kornblith</surname><given-names>A. B.</given-names></name>
<name><surname>Herndon</surname><given-names>J. E.</given-names><suffix>II</suffix></name>
<name><surname>Silverman</surname><given-names>L. R.</given-names></name>
<name><surname>Demakos</surname><given-names>E. P.</given-names></name>
<name><surname>Odchimar-Reissig</surname><given-names>R.</given-names></name>
<name><surname>Holland</surname><given-names>J. F.</given-names></name>
<name><surname>Powell</surname><given-names>B. L.</given-names></name>
<name><surname>DeCastro</surname><given-names>C.</given-names></name>
<name><surname>Ellerton</surname><given-names>J.</given-names></name>
<name><surname>Larson</surname><given-names>R. A.</given-names></name><etal/>
</person-group>. <article-title>Impact of Azacytidine on the Quality of Life of Patients with Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study</article-title>. <source>J. Clin. Oncol</source>. <year>2002</year>, <volume>20</volume>, <fpage>2441</fpage>–<lpage>2452</lpage>.</citation>
</ref>
<ref id="bibr124-1087057111421212">
<label>124.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silverman</surname><given-names>L. R.</given-names></name>
<name><surname>McKenzie</surname><given-names>D. R.</given-names></name>
<name><surname>Peterson</surname><given-names>B. L.</given-names></name>
<name><surname>Holland</surname><given-names>J. F.</given-names></name>
<name><surname>Backstrom</surname><given-names>J. T.</given-names></name>
<name><surname>Beach</surname><given-names>C. L.</given-names></name>
<name><surname>Larson</surname><given-names>R. A.</given-names></name>
</person-group> <article-title>Further Analysis of Trials with Azacitidine in Patients with Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B</article-title>. <source>J. Clin. Oncol</source>. <year>2006</year>, <volume>24</volume>, <fpage>3895</fpage>–<lpage>3903</lpage>.</citation>
</ref>
<ref id="bibr125-1087057111421212">
<label>125.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fenaux</surname><given-names>P.</given-names></name>
<name><surname>Mufti</surname><given-names>G. J.</given-names></name>
<name><surname>Hellstrom-Lindberg</surname><given-names>E.</given-names></name>
<name><surname>Santini</surname><given-names>V.</given-names></name>
<name><surname>Finelli</surname><given-names>C.</given-names></name>
<name><surname>Giagounidis</surname><given-names>A.</given-names></name>
<name><surname>Schoch</surname><given-names>R.</given-names></name>
<name><surname>Gattermann</surname><given-names>N.</given-names></name>
<name><surname>Sanz</surname><given-names>G.</given-names></name>
<name><surname>List</surname><given-names>A.</given-names></name><etal/>
</person-group>. <article-title>Efficacy of Azacitidine Compared with That of Conventional Care Regimens in the Treatment of Higher-Risk Myelodysplastic Syndromes: A Randomised, Open-Label, Phase III Study</article-title>. <source>Lancet Oncol</source>. <year>2009</year>, <volume>10</volume>, <fpage>223</fpage>–<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr126-1087057111421212">
<label>126.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kantarjian</surname><given-names>H.</given-names></name>
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
<name><surname>Rosenfeld</surname><given-names>C. S.</given-names></name>
<name><surname>Bennett</surname><given-names>J. M.</given-names></name>
<name><surname>Albitar</surname><given-names>M.</given-names></name>
<name><surname>DiPersio</surname><given-names>J.</given-names></name>
<name><surname>Klimek</surname><given-names>V.</given-names></name>
<name><surname>Slack</surname><given-names>J.</given-names></name>
<name><surname>de Castro</surname><given-names>C.</given-names></name>
<name><surname>Ravandi</surname><given-names>F.</given-names></name><etal/>
</person-group>. <article-title>Decitabine Improves Patient Outcomes in Myelodysplastic Syndromes: Results of a Phase III Randomized Study</article-title>. <source>Cancer</source> <year>2006</year>, <volume>106</volume>, <fpage>1794</fpage>–<lpage>1803</lpage>.</citation>
</ref>
<ref id="bibr127-1087057111421212">
<label>127.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
<name><surname>Garcia-Manero</surname><given-names>G.</given-names></name>
<name><surname>Giles</surname><given-names>F. J.</given-names></name>
<name><surname>Mannari</surname><given-names>R.</given-names></name>
<name><surname>Thomas</surname><given-names>D.</given-names></name>
<name><surname>Faderl</surname><given-names>S.</given-names></name>
<name><surname>Bayar</surname><given-names>E.</given-names></name>
<name><surname>Lyons</surname><given-names>J.</given-names></name>
<name><surname>Rosenfeld</surname><given-names>C. S.</given-names></name>
<name><surname>Cortes</surname><given-names>J.</given-names></name><etal/>
</person-group>. <article-title>Phase 1 Study of Low-Dose Prolonged Exposure Schedules of the Hypomethylating Agent 5-Aza-2′-Deoxycytidine (Decitabine) in Hematopoietic Malignancies</article-title>. <source>Blood</source> <year>2004</year>, <volume>103</volume>, <fpage>1635</fpage>–<lpage>1640</lpage>.</citation>
</ref>
<ref id="bibr128-1087057111421212">
<label>128.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kantarjian</surname><given-names>H.</given-names></name>
<name><surname>Oki</surname><given-names>Y.</given-names></name>
<name><surname>Garcia-Manero</surname><given-names>G.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>O’Brien</surname><given-names>S.</given-names></name>
<name><surname>Cortes</surname><given-names>J.</given-names></name>
<name><surname>Faderl</surname><given-names>S.</given-names></name>
<name><surname>Bueso-Ramos</surname><given-names>C.</given-names></name>
<name><surname>Ravandi</surname><given-names>F.</given-names></name>
<name><surname>Estrov</surname><given-names>Z.</given-names></name><etal/>
</person-group>. <article-title>Results of a Randomized Study of 3 Schedules of Low-Dose Decitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia</article-title>. <source>Blood</source> <year>2007</year>, <volume>109</volume>, <fpage>52</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr129-1087057111421212">
<label>129.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steensma</surname><given-names>D. P.</given-names></name>
<name><surname>Baer</surname><given-names>M. R.</given-names></name>
<name><surname>Slack</surname><given-names>J. L.</given-names></name>
<name><surname>Buckstein</surname><given-names>R.</given-names></name>
<name><surname>Godley</surname><given-names>L. A.</given-names></name>
<name><surname>Garcia-Manero</surname><given-names>G.</given-names></name>
<name><surname>Albitar</surname><given-names>M.</given-names></name>
<name><surname>Larsen</surname><given-names>J. S.</given-names></name>
<name><surname>Arora</surname><given-names>S.</given-names></name>
<name><surname>Cullen</surname><given-names>M. T.</given-names></name><etal/>
</person-group>. <article-title>Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial</article-title>. <source>J. Clin. Oncol</source>. <year>2009</year>, <volume>27</volume>, <fpage>3842</fpage>–<lpage>3848</lpage>.</citation>
</ref>
<ref id="bibr130-1087057111421212">
<label>130.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cashen</surname><given-names>A. F.</given-names></name>
<name><surname>Schiller</surname><given-names>G. J.</given-names></name>
<name><surname>O’Donnell</surname><given-names>M. R.</given-names></name>
<name><surname>DiPersio</surname><given-names>J. F.</given-names></name>
</person-group> <article-title>Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients with Acute Myeloid Leukemia</article-title>. <source>J. Clin. Oncol</source>. <year>2010</year>, <volume>28</volume>, <fpage>556</fpage>–<lpage>561</lpage>.</citation>
</ref>
<ref id="bibr131-1087057111421212">
<label>131.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shen</surname><given-names>L.</given-names></name>
<name><surname>Kantarjian</surname><given-names>H.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Lin</surname><given-names>E.</given-names></name>
<name><surname>Shan</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Berry</surname><given-names>D.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
<name><surname>Pierce</surname><given-names>S.</given-names></name><etal/>
</person-group>. <article-title>DNA Methylation Predicts Survival and Response to Therapy in Patients with Myelodysplastic Syndromes</article-title>. <source>J. Clin. Oncol</source>. <year>2010</year>, <volume>28</volume>, <fpage>605</fpage>–<lpage>613</lpage>.</citation>
</ref>
<ref id="bibr132-1087057111421212">
<label>132.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fang</surname><given-names>F.</given-names></name>
<name><surname>Balch</surname><given-names>C.</given-names></name>
<name><surname>Schilder</surname><given-names>J.</given-names></name>
<name><surname>Breen</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Shen</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Kulesavage</surname><given-names>C.</given-names></name>
<name><surname>Snyder</surname><given-names>A. J.</given-names></name>
<name><surname>Nephew</surname><given-names>K. P.</given-names></name><etal/>
</person-group>. <article-title>A Phase 1 and Pharmacodynamic Study of Decitabine in Combination with Carboplatin in Patients with Recurrent, Platinum-Resistant, Epithelial Ovarian Cancer</article-title>. <source>Cancer</source> <year>2010</year>, <volume>116</volume>, <fpage>4043</fpage>–<lpage>4053</lpage>.</citation>
</ref>
<ref id="bibr133-1087057111421212">
<label>133.</label>
<citation citation-type="web"><comment><ext-link ext-link-type="uri" xlink:href="http://www.standup2cancer.org/node/4446">http://www.standup2cancer.org/node/4446</ext-link></comment></citation>
</ref>
<ref id="bibr134-1087057111421212">
<label>134.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Byun</surname><given-names>H. M.</given-names></name>
<name><surname>Choi</surname><given-names>S. H.</given-names></name>
<name><surname>Laird</surname><given-names>P. W.</given-names></name>
<name><surname>Trinh</surname><given-names>B.</given-names></name>
<name><surname>Siddiqui</surname><given-names>M. A.</given-names></name>
<name><surname>Marquez</surname><given-names>V. E.</given-names></name>
<name><surname>Yang</surname><given-names>A. S.</given-names></name>
</person-group> <article-title>2′-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-Azacytidine: A Novel Inhibitor of DNA Methyltransferase That Requires Activation by Human Carboxylesterase 1</article-title>. <source>Cancer Lett</source>. <year>2008</year>, <volume>266</volume>, <fpage>238</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr135-1087057111421212">
<label>135.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoo</surname><given-names>C. B.</given-names></name>
<name><surname>Jeong</surname><given-names>S.</given-names></name>
<name><surname>Egger</surname><given-names>G.</given-names></name>
<name><surname>Liang</surname><given-names>G.</given-names></name>
<name><surname>Phiasivongsa</surname><given-names>P.</given-names></name>
<name><surname>Tang</surname><given-names>C.</given-names></name>
<name><surname>Redkar</surname><given-names>S.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>Delivery of 5-Aza-2′-Deoxycytidine to Cells Using Oligodeoxynucleotides</article-title>. <source>Cancer Res</source>. <year>2007</year>, <volume>67</volume>, <fpage>6400</fpage>–<lpage>6408</lpage>.</citation>
</ref>
<ref id="bibr136-1087057111421212">
<label>136.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chuang</surname><given-names>J. C.</given-names></name>
<name><surname>Warner</surname><given-names>S. L.</given-names></name>
<name><surname>Vollmer</surname><given-names>D.</given-names></name>
<name><surname>Vankayalapati</surname><given-names>H.</given-names></name>
<name><surname>Redkar</surname><given-names>S.</given-names></name>
<name><surname>Bearss</surname><given-names>D. J.</given-names></name>
<name><surname>Qiu</surname><given-names>X.</given-names></name>
<name><surname>Yoo</surname><given-names>C. B.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>S110, a 5-Aza-2′-Deoxycytidine-Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In Vivo and Can Reduce Tumor Growth</article-title>. <source>Mol. Cancer Ther</source>. <year>2010</year>, <volume>9</volume>, <fpage>1443</fpage>–<lpage>1450</lpage>.</citation>
</ref>
<ref id="bibr137-1087057111421212">
<label>137.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lavelle</surname><given-names>D.</given-names></name>
<name><surname>Saunthararajah</surname><given-names>Y.</given-names></name>
<name><surname>Vaitkus</surname><given-names>K.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
<name><surname>Banzon</surname><given-names>V.</given-names></name>
<name><surname>Phiasivongsva</surname><given-names>P.</given-names></name>
<name><surname>Redkar</surname><given-names>S.</given-names></name>
<name><surname>Kanekal</surname><given-names>S.</given-names></name>
<name><surname>Bearss</surname><given-names>D.</given-names></name>
<name><surname>Shi</surname><given-names>C.</given-names></name><etal/>
</person-group>. <article-title>S110, a Novel Decitabine Dinucleotide, Increases Fetal Hemoglobin Levels in Baboons (<italic>P. anubis</italic>)</article-title>. <source>J. Transl. Med</source>. <year>2010</year>, <volume>8</volume>, <fpage>92</fpage>.</citation>
</ref>
<ref id="bibr138-1087057111421212">
<label>138.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brueckner</surname><given-names>B.</given-names></name>
<name><surname>Rius</surname><given-names>M.</given-names></name>
<name><surname>Markelova</surname><given-names>M. R.</given-names></name>
<name><surname>Fichtner</surname><given-names>I.</given-names></name>
<name><surname>Hals</surname><given-names>P. A.</given-names></name>
<name><surname>Sandvold</surname><given-names>M. L.</given-names></name>
</person-group> <article-title>Lyko F: Delivery of 5-Azacytidine to Human Cancer Cells by Elaidic Acid Esterification Increases Therapeutic Drug Efficacy</article-title>. <source>Mol. Cancer Ther</source>. <year>2010</year>, <volume>9</volume>, <fpage>1256</fpage>–<lpage>1264</lpage>.</citation>
</ref>
<ref id="bibr139-1087057111421212">
<label>139.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McGregor</surname><given-names>D. B.</given-names></name>
<name><surname>Brown</surname><given-names>A. G.</given-names></name>
<name><surname>Cattanach</surname><given-names>P.</given-names></name>
<name><surname>Shepherd</surname><given-names>W.</given-names></name>
<name><surname>Riach</surname><given-names>C.</given-names></name>
<name><surname>Daston</surname><given-names>D. S.</given-names></name>
<name><surname>Caspary</surname><given-names>W. J.</given-names></name>
</person-group> <article-title>TFT and 6TG Resistance of Mouse Lymphoma Cells to Analogs of Azacytidine</article-title>. <source>Carcinogenesis</source> <year>1989</year>, <volume>10</volume>, <fpage>2003</fpage>–<lpage>2008</lpage>.</citation>
</ref>
<ref id="bibr140-1087057111421212">
<label>140.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osterman</surname><given-names>D. G.</given-names></name>
<name><surname>DePillis</surname><given-names>G. D.</given-names></name>
<name><surname>Wu</surname><given-names>J. C.</given-names></name>
<name><surname>Matsuda</surname><given-names>A.</given-names></name>
<name><surname>Santi</surname><given-names>D. V.</given-names></name>
</person-group> <article-title>5-Fluorocytosine in DNA Is a Mechanism-Based Inhibitor of HhaI Methylase</article-title>. <source>Biochemistry</source> <year>1988</year>, <volume>27</volume>, <fpage>5204</fpage>–<lpage>5210</lpage>.</citation>
</ref>
<ref id="bibr141-1087057111421212">
<label>141.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Champion</surname><given-names>C.</given-names></name>
<name><surname>Guianvarc’h</surname><given-names>D.</given-names></name>
<name><surname>Senamaud-Beaufort</surname><given-names>C.</given-names></name>
<name><surname>Jurkowska</surname><given-names>R. Z.</given-names></name>
<name><surname>Jeltsch</surname><given-names>A.</given-names></name>
<name><surname>Ponger</surname><given-names>L.</given-names></name>
<name><surname>Arimondo</surname><given-names>P. B.</given-names></name>
<name><surname>Guieysse-Peugeot</surname><given-names>A. L.</given-names></name>
</person-group> <article-title>Mechanistic Insights on the Inhibition of c5 DNA Methyltransferases by Zebularine</article-title>. <source>PLoS One</source> <year>2010</year>, <volume>5</volume>, <fpage>e12388</fpage>.</citation>
</ref>
<ref id="bibr142-1087057111421212">
<label>142.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newman</surname><given-names>E. M.</given-names></name>
<name><surname>Santi</surname><given-names>D. V.</given-names></name>
</person-group> <article-title>Metabolism and Mechanism of Action of 5-Fluorodeoxycytidine</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source>. <year>1982</year>, <volume>79</volume>, <fpage>6419</fpage>–<lpage>6423</lpage>.</citation>
</ref>
<ref id="bibr143-1087057111421212">
<label>143.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flotho</surname><given-names>C.</given-names></name>
<name><surname>Claus</surname><given-names>R.</given-names></name>
<name><surname>Batz</surname><given-names>C.</given-names></name>
<name><surname>Schneider</surname><given-names>M.</given-names></name>
<name><surname>Sandrock</surname><given-names>I.</given-names></name>
<name><surname>Ihde</surname><given-names>S.</given-names></name>
<name><surname>Plass</surname><given-names>C.</given-names></name>
<name><surname>Niemeyer</surname><given-names>C. M.</given-names></name>
<name><surname>Lubbert</surname><given-names>M.</given-names></name>
</person-group> <article-title>The DNA Methyltransferase Inhibitors Azacitidine, Decitabine and Zebularine Exert Differential Effects on Cancer Gene Expression in Acute Myeloid Leukemia Cells</article-title>. <source>Leukemia</source> <year>2009</year>, <volume>23</volume>, <fpage>1019</fpage>–<lpage>1028</lpage>.</citation>
</ref>
<ref id="bibr144-1087057111421212">
<label>144.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amato</surname><given-names>R. J.</given-names></name>
</person-group> <article-title>Inhibition of DNA Methylation by Antisense Oligonucleotide MG98 as Cancer Therapy</article-title>. <source>Clin. Genitourin. Cancer</source> <year>2007</year>, <volume>5</volume>, <fpage>422</fpage>–<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr145-1087057111421212">
<label>145.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winquist</surname><given-names>E.</given-names></name>
<name><surname>Knox</surname><given-names>J.</given-names></name>
<name><surname>Ayoub</surname><given-names>J. P.</given-names></name>
<name><surname>Wood</surname><given-names>L.</given-names></name>
<name><surname>Wainman</surname><given-names>N.</given-names></name>
<name><surname>Reid</surname><given-names>G. K.</given-names></name>
<name><surname>Pearce</surname><given-names>L.</given-names></name>
<name><surname>Shah</surname><given-names>A.</given-names></name>
<name><surname>Eisenhauer</surname><given-names>E.</given-names></name>
</person-group> <article-title>Phase II Trial of DNA Methyltransferase 1 Inhibition with the Antisense Oligonucleotide MG98 in Patients with Metastatic Renal Carcinoma: A National Cancer Institute of Canada Clinical Trials Group Investigational New Drug Study</article-title>. <source>Invest. New Drugs</source> <year>2006</year>, <volume>24</volume>, <fpage>159</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr146-1087057111421212">
<label>146.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klisovic</surname><given-names>R. B.</given-names></name>
<name><surname>Blum</surname><given-names>W.</given-names></name>
<name><surname>Wei</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
<name><surname>Vukosavljevic</surname><given-names>T.</given-names></name>
<name><surname>Kefauver</surname><given-names>C.</given-names></name>
<name><surname>Huynh</surname><given-names>L.</given-names></name>
<name><surname>Pang</surname><given-names>J.</given-names></name><etal/>
</person-group>. <article-title>Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia</article-title>. <source>Clin. Cancer Res</source>. <year>2008</year>, <volume>14</volume>, <fpage>3889</fpage>–<lpage>3895</lpage>.</citation>
</ref>
<ref id="bibr147-1087057111421212">
<label>147.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Plummer</surname><given-names>R.</given-names></name>
<name><surname>Vidal</surname><given-names>L.</given-names></name>
<name><surname>Griffin</surname><given-names>M.</given-names></name>
<name><surname>Lesley</surname><given-names>M.</given-names></name>
<name><surname>de Bono</surname><given-names>J.</given-names></name>
<name><surname>Coulthard</surname><given-names>S.</given-names></name>
<name><surname>Sludden</surname><given-names>J.</given-names></name>
<name><surname>Siu</surname><given-names>L. L.</given-names></name>
<name><surname>Chen</surname><given-names>E. X.</given-names></name>
<name><surname>Oza</surname><given-names>A. M.</given-names></name><etal/>
</person-group>. <article-title>Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors</article-title>. <source>Clin. Cancer Res</source>. <year>2009</year>, <volume>15</volume>, <fpage>3177</fpage>–<lpage>3183</lpage>.</citation>
</ref>
<ref id="bibr148-1087057111421212">
<label>148.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garzon</surname><given-names>R.</given-names></name>
<name><surname>Heaphy</surname><given-names>C. E.</given-names></name>
<name><surname>Havelange</surname><given-names>V.</given-names></name>
<name><surname>Fabbri</surname><given-names>M.</given-names></name>
<name><surname>Volinia</surname><given-names>S.</given-names></name>
<name><surname>Tsao</surname><given-names>T.</given-names></name>
<name><surname>Zanesi</surname><given-names>N.</given-names></name>
<name><surname>Kornblau</surname><given-names>S. M.</given-names></name>
<name><surname>Marcucci</surname><given-names>G.</given-names></name>
<name><surname>Calin</surname><given-names>G. A.</given-names></name><etal/>
</person-group>. <article-title>MicroRNA 29b Functions in Acute Myeloid Leukemia</article-title>. <source>Blood</source> <year>2009</year>, <volume>114</volume>, <fpage>5331</fpage>–<lpage>5341</lpage>.</citation>
</ref>
<ref id="bibr149-1087057111421212">
<label>149.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qin</surname><given-names>T.</given-names></name>
<name><surname>Jelinek</surname><given-names>J.</given-names></name>
<name><surname>Si</surname><given-names>J.</given-names></name>
<name><surname>Shu</surname><given-names>J.</given-names></name>
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
</person-group> <article-title>Mechanisms of Resistance to 5-Aza-2′-Deoxycytidine in Human Cancer Cell Lines</article-title>. <source>Blood</source> <year>2009</year>, <volume>113</volume>, <fpage>659</fpage>–<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr150-1087057111421212">
<label>150.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cornacchia</surname><given-names>E.</given-names></name>
<name><surname>Golbus</surname><given-names>J.</given-names></name>
<name><surname>Maybaum</surname><given-names>J.</given-names></name>
<name><surname>Strahler</surname><given-names>J.</given-names></name>
<name><surname>Hanash</surname><given-names>S.</given-names></name>
<name><surname>Richardson</surname><given-names>B.</given-names></name>
</person-group> <article-title>Hydralazine and Procainamide Inhibit T Cell DNA Methylation and Induce Autoreactivity</article-title>. <source>J. Immunol</source>. <year>1988</year>, <volume>140</volume>, <fpage>2197</fpage>–<lpage>2200</lpage>.</citation>
</ref>
<ref id="bibr151-1087057111421212">
<label>151.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Segura-Pacheco</surname><given-names>B.</given-names></name>
<name><surname>Trejo-Becerril</surname><given-names>C.</given-names></name>
<name><surname>Perez-Cardenas</surname><given-names>E.</given-names></name>
<name><surname>Taja-Chayeb</surname><given-names>L.</given-names></name>
<name><surname>Mariscal</surname><given-names>I.</given-names></name>
<name><surname>Chavez</surname><given-names>A.</given-names></name>
<name><surname>Acuna</surname><given-names>C.</given-names></name>
<name><surname>Salazar</surname><given-names>A. M.</given-names></name>
<name><surname>Lizano</surname><given-names>M.</given-names></name>
<name><surname>Duenas-Gonzalez</surname><given-names>A.</given-names></name>
</person-group> <article-title>Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy</article-title>. <source>Clin. Cancer Res</source>. <year>2003</year>, <volume>9</volume>, <fpage>1596</fpage>–<lpage>1603</lpage>.</citation>
</ref>
<ref id="bibr152-1087057111421212">
<label>152.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deng</surname><given-names>C.</given-names></name>
<name><surname>Lu</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Rao</surname><given-names>T.</given-names></name>
<name><surname>Attwood</surname><given-names>J.</given-names></name>
<name><surname>Yung</surname><given-names>R.</given-names></name>
<name><surname>Richardson</surname><given-names>B.</given-names></name>
</person-group> <article-title>Hydralazine May Induce Autoimmunity by Inhibiting Extracellular Signal-Regulated Kinase Pathway Signaling</article-title>. <source>Arthritis Rheum</source>. <year>2003</year>, <volume>48</volume>, <fpage>746</fpage>–<lpage>756</lpage>.</citation>
</ref>
<ref id="bibr153-1087057111421212">
<label>153.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chuang</surname><given-names>J. C.</given-names></name>
<name><surname>Yoo</surname><given-names>C. B.</given-names></name>
<name><surname>Kwan</surname><given-names>J. M.</given-names></name>
<name><surname>Li</surname><given-names>T. W.</given-names></name>
<name><surname>Liang</surname><given-names>G.</given-names></name>
<name><surname>Yang</surname><given-names>A. S.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>Comparison of Biological Effects of Non-Nucleoside DNA Methylation Inhibitors versus 5-Aza-2′-Deoxycytidine</article-title>. <source>Mol. Cancer Ther</source>. <year>2005</year>, <volume>4</volume>, <fpage>1515</fpage>–<lpage>1520</lpage>.</citation>
</ref>
<ref id="bibr154-1087057111421212">
<label>154.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coronel</surname><given-names>J.</given-names></name>
<name><surname>Cetina</surname><given-names>L.</given-names></name>
<name><surname>Pacheco</surname><given-names>I.</given-names></name>
<name><surname>Trejo-Becerril</surname><given-names>C.</given-names></name>
<name><surname>Gonzalez-Fierro</surname><given-names>A.</given-names></name>
<name><surname>de</surname><given-names>la</given-names></name>
<name><surname>Cruz-Hernandez</surname><given-names>E.</given-names></name>
<name><surname>Perez-Cardenas</surname><given-names>E.</given-names></name>
<name><surname>Taja-Chayeb</surname><given-names>L.</given-names></name>
<name><surname>Arias-Bofill</surname><given-names>D.</given-names></name>
<name><surname>Candelaria</surname><given-names>M.</given-names></name><etal/>
</person-group>. <article-title>A Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Chemotherapy Plus Epigenetic Therapy with Hydralazine Valproate for Advanced Cervical Cancer: Preliminary Results</article-title>. <source>Med Oncol</source> <year>2010</year> <month>Oct</month> <day>8</day>. [<comment>Epub ahead of print</comment>]</citation>
</ref>
<ref id="bibr155-1087057111421212">
<label>155.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Candelaria</surname><given-names>M.</given-names></name>
<name><surname>Herrera</surname><given-names>A.</given-names></name>
<name><surname>Labardini</surname><given-names>J.</given-names></name>
<name><surname>Gonzalez-Fierro</surname><given-names>A.</given-names></name>
<name><surname>Trejo-Becerril</surname><given-names>C.</given-names></name>
<name><surname>Taja-Chayeb</surname><given-names>L.</given-names></name>
<name><surname>Perez-Cardenas</surname><given-names>E.</given-names></name>
<name><surname>de</surname><given-names>la</given-names></name>
<name><surname>Cruz-Hernandez</surname><given-names>E.</given-names></name>
<name><surname>Arias-Bofill</surname><given-names>D.</given-names></name>
<name><surname>Vidal</surname><given-names>S.</given-names></name><etal/>
</person-group>. <article-title>Hydralazine and Magnesium Valproate as Epigenetic Treatment for Myelodysplastic Syndrome: Preliminary Results of a Phase-II Trial</article-title>. <source>Ann. Hematol</source>. <year>2011</year>, <volume>90</volume>, <fpage>379</fpage>–<lpage>387</lpage>.</citation>
</ref>
<ref id="bibr156-1087057111421212">
<label>156.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villar-Garea</surname><given-names>A.</given-names></name>
<name><surname>Fraga</surname><given-names>M. F.</given-names></name>
<name><surname>Espada</surname><given-names>J.</given-names></name>
<name><surname>Esteller</surname><given-names>M.</given-names></name>
</person-group> <article-title>Procaine Is a DNA-Demethylating Agent with Growth-Inhibitory Effects in Human Cancer Cells</article-title>. <source>Cancer Res</source>. <year>2003</year>, <volume>63</volume>, <fpage>4984</fpage>–<lpage>4989</lpage>.</citation>
</ref>
<ref id="bibr157-1087057111421212">
<label>157.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stresemann</surname><given-names>C.</given-names></name>
<name><surname>Brueckner</surname><given-names>B.</given-names></name>
<name><surname>Musch</surname><given-names>T.</given-names></name>
<name><surname>Stopper</surname><given-names>H.</given-names></name>
<name><surname>Lyko</surname><given-names>F.</given-names></name>
</person-group> <article-title>Functional Diversity of DNA Methyltransferase Inhibitors in Human Cancer Cell Lines</article-title>. <source>Cancer Res</source>. <year>2006</year>, <volume>66</volume>, <fpage>2794</fpage>–<lpage>2800</lpage>.</citation>
</ref>
<ref id="bibr158-1087057111421212">
<label>158.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fang</surname><given-names>M. Z.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Ai</surname><given-names>N.</given-names></name>
<name><surname>Hou</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>H.</given-names></name>
<name><surname>Welsh</surname><given-names>W.</given-names></name>
<name><surname>Yang</surname><given-names>C. S.</given-names></name>
</person-group> <article-title>Tea Polyphenol (–)-Epigallocatechin-3-Gallate Inhibits DNA Methyltransferase and Reactivates Methylation-Silenced Genes in Cancer Cell Lines</article-title>. <source>Cancer Res</source>. <year>2003</year>, <volume>63</volume>, <fpage>7563</fpage>–<lpage>7570</lpage>.</citation>
</ref>
<ref id="bibr159-1087057111421212">
<label>159.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siedlecki</surname><given-names>P.</given-names></name>
<name><surname>Garcia Boy</surname><given-names>R.</given-names></name>
<name><surname>Musch</surname><given-names>T.</given-names></name>
<name><surname>Brueckner</surname><given-names>B.</given-names></name>
<name><surname>Suhai</surname><given-names>S.</given-names></name>
<name><surname>Lyko</surname><given-names>F.</given-names></name>
<name><surname>Zielenkiewicz</surname><given-names>P.</given-names></name>
</person-group> <article-title>Discovery of Two Novel, Small-Molecule Inhibitors of DNA Methylation</article-title>. <source>J. Med. Chem</source>. <year>2006</year>, <volume>49</volume>, <fpage>678</fpage>–<lpage>683</lpage>.</citation>
</ref>
<ref id="bibr160-1087057111421212">
<label>160.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brueckner</surname><given-names>B.</given-names></name>
<name><surname>Garcia Boy</surname><given-names>R.</given-names></name>
<name><surname>Siedlecki</surname><given-names>P.</given-names></name>
<name><surname>Musch</surname><given-names>T.</given-names></name>
<name><surname>Kliem</surname><given-names>H. C.</given-names></name>
<name><surname>Zielenkiewicz</surname><given-names>P.</given-names></name>
<name><surname>Suhai</surname><given-names>S.</given-names></name>
<name><surname>Wiessler</surname><given-names>M.</given-names></name>
<name><surname>Lyko</surname><given-names>F.</given-names></name>
</person-group> <article-title>Epigenetic Reactivation of Tumor Suppressor Genes by a Novel Small-Molecule Inhibitor of Human DNA Methyltransferases</article-title>. <source>Cancer Res</source>. <year>2005</year>, <volume>65</volume>, <fpage>6305</fpage>–<lpage>6311</lpage>.</citation>
</ref>
<ref id="bibr161-1087057111421212">
<label>161.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>R. K.</given-names></name>
<name><surname>Hsu</surname><given-names>C. H.</given-names></name>
<name><surname>Wang</surname><given-names>Y. C.</given-names></name>
</person-group> <article-title>Mithramycin A Inhibits DNA Methyltransferase and Metastasis Potential of Lung Cancer Cells</article-title>. <source>Anticancer Drugs</source> <year>2007</year>, <volume>18</volume>, <fpage>1157</fpage>–<lpage>1164</lpage>.</citation>
</ref>
<ref id="bibr162-1087057111421212">
<label>162.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Datta</surname><given-names>J.</given-names></name>
<name><surname>Ghoshal</surname><given-names>K.</given-names></name>
<name><surname>Denny</surname><given-names>W. A.</given-names></name>
<name><surname>Gamage</surname><given-names>S. A.</given-names></name>
<name><surname>Brooke</surname><given-names>D. G.</given-names></name>
<name><surname>Phiasivongsa</surname><given-names>P.</given-names></name>
<name><surname>Redkar</surname><given-names>S.</given-names></name>
<name><surname>Jacob</surname><given-names>S. T.</given-names></name>
</person-group> <article-title>A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation</article-title>. <source>Cancer Res</source>. <year>2009</year>, <volume>69</volume>, <fpage>4277</fpage>–<lpage>4285</lpage>.</citation>
</ref>
<ref id="bibr163-1087057111421212">
<label>163.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuck</surname><given-names>D.</given-names></name>
<name><surname>Caulfield</surname><given-names>T.</given-names></name>
<name><surname>Lyko</surname><given-names>F.</given-names></name>
<name><surname>Medina-Franco</surname><given-names>J. L.</given-names></name>
</person-group> <article-title>Nanaomycin A Selectively Inhibits DNMT3B and Reactivates Silenced Tumor Suppressor Genes in Human Cancer Cells</article-title>. <source>Mol. Cancer Ther</source>. <year>2010</year>, <volume>9</volume>, <fpage>3015</fpage>–<lpage>3023</lpage>.</citation>
</ref>
<ref id="bibr164-1087057111421212">
<label>164.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuck</surname><given-names>D.</given-names></name>
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Lyko</surname><given-names>F.</given-names></name>
<name><surname>Medina-Franco</surname><given-names>J. L.</given-names></name>
</person-group> <article-title>Novel and Selective DNA Methyltransferase Inhibitors: Docking-Based Virtual Screening and Experimental Evaluation</article-title>. <source>Bioorg. Med. Chem</source>. <year>2010</year>, <volume>18</volume>, <fpage>822</fpage>–<lpage>829</lpage>.</citation>
</ref>
<ref id="bibr165-1087057111421212">
<label>165.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname><given-names>J.</given-names></name>
<name><surname>Rechkoblit</surname><given-names>O.</given-names></name>
<name><surname>Bestor</surname><given-names>T. H.</given-names></name>
<name><surname>Patel</surname><given-names>D. J.</given-names></name>
</person-group> <article-title>Structure of DNMT1-DNA Complex Reveals a Role for Autoinhibition in Maintenance DNA Methylation</article-title>. <source>Science</source> <year>2011</year>, <volume>331</volume>, <fpage>1036</fpage>–<lpage>1040</lpage>.</citation>
</ref>
<ref id="bibr166-1087057111421212">
<label>166.</label>
<citation citation-type="web"><comment><ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/chembldb/index.php">http://www.ebi.ac.uk/chembldb/index.php</ext-link></comment></citation>
</ref>
<ref id="bibr167-1087057111421212">
<label>167.</label>
<citation citation-type="web"><comment><ext-link ext-link-type="uri" xlink:href="http://www.bindingdb.org">http://www.bindingdb.org</ext-link></comment></citation>
</ref>
<ref id="bibr168-1087057111421212">
<label>168.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Lay</surname><given-names>F.</given-names></name>
<name><surname>Han</surname><given-names>H.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>Targeting DNA Methylation for Epigenetic Therapy</article-title>. <source>Trends Pharmacol. Sci</source>. <year>2010</year>, <volume>31</volume>, <fpage>536</fpage>–<lpage>546</lpage>.</citation>
</ref>
<ref id="bibr169-1087057111421212">
<label>169.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Medina-Franco</surname><given-names>J. L.</given-names></name>
<name><surname>Caulfield</surname><given-names>T.</given-names></name>
</person-group> <article-title>Advances in the Computational Development of DNA Methyltransferase Inhibitors</article-title>. <source>Drug Discov. Today</source> <year>2011</year>, <volume>16</volume>, <fpage>418</fpage>–<lpage>425</lpage>.</citation>
</ref>
<ref id="bibr170-1087057111421212">
<label>170.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Kelly</surname><given-names>T. K.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>Epigenetics in cancer</article-title>. <source>Carcinogenesis</source> <year>2010</year>, <volume>31</volume>, <fpage>27</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr171-1087057111421212">
<label>171.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>J. C.</given-names></name>
<name><surname>Jeong</surname><given-names>S.</given-names></name>
<name><surname>Liang</surname><given-names>G.</given-names></name>
<name><surname>Takai</surname><given-names>D.</given-names></name>
<name><surname>Fatemi</surname><given-names>M.</given-names></name>
<name><surname>Tsai</surname><given-names>Y. C.</given-names></name>
<name><surname>Egger</surname><given-names>G.</given-names></name>
<name><surname>Gal-Yam</surname><given-names>E. N.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>Role of Nucleosomal Occupancy in the Epigenetic Silencing of the MLH1 CpG Island</article-title>. <source>Cancer Cell</source> <year>2007</year>, <volume>12</volume>, <fpage>432</fpage>–<lpage>444</lpage>.</citation>
</ref>
<ref id="bibr172-1087057111421212">
<label>172.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Margueron</surname><given-names>R.</given-names></name>
<name><surname>Reinberg</surname><given-names>D.</given-names></name>
</person-group> <article-title>The Polycomb Complex PRC2 and Its Mark in Life</article-title>. <source>Nature</source> <year>2011</year>, <volume>469</volume>, <fpage>343</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr173-1087057111421212">
<label>173.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pradhan</surname><given-names>S.</given-names></name>
<name><surname>Chin</surname><given-names>H. G.</given-names></name>
<name><surname>Esteve</surname><given-names>P. O.</given-names></name>
<name><surname>Jacobsen</surname><given-names>S. E.</given-names></name>
</person-group> <article-title>SET7/9 Mediated Methylation of Non-Histone Proteins in Mammalian Cells</article-title>. <source>Epigenetics</source> <year>2009</year>, <volume>4</volume>, <fpage>383</fpage>–<lpage>387</lpage>.</citation>
</ref>
<ref id="bibr174-1087057111421212">
<label>174.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nicholson</surname><given-names>T. B.</given-names></name>
<name><surname>Chen</surname><given-names>T.</given-names></name>
</person-group> <article-title>LSD1 Demethylates Histone and Non-Histone Proteins</article-title>. <source>Epigenetics</source> <year>2009</year>, <volume>4</volume>, <fpage>129</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr175-1087057111421212">
<label>175.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taby</surname><given-names>R.</given-names></name>
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
</person-group> <article-title>Cancer Epigenetics</article-title>. <source>CA Cancer J. Clin</source>. <year>2010</year>, <volume>60</volume>, <fpage>376</fpage>–<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr176-1087057111421212">
<label>176.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gollob</surname><given-names>J. A.</given-names></name>
<name><surname>Sciambi</surname><given-names>C. J.</given-names></name>
<name><surname>Peterson</surname><given-names>B. L.</given-names></name>
<name><surname>Richmond</surname><given-names>T.</given-names></name>
<name><surname>Thoreson</surname><given-names>M.</given-names></name>
<name><surname>Moran</surname><given-names>K.</given-names></name>
<name><surname>Dressman</surname><given-names>H. K.</given-names></name>
<name><surname>Jelinek</surname><given-names>J.</given-names></name>
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
</person-group> <article-title>Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma</article-title>. <source>Clin. Cancer Res</source>. <year>2006</year>, <volume>12</volume>, <fpage>4619</fpage>–<lpage>4627</lpage>.</citation>
</ref>
<ref id="bibr177-1087057111421212">
<label>177.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soriano</surname><given-names>A. O.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Faderl</surname><given-names>S.</given-names></name>
<name><surname>Estrov</surname><given-names>Z.</given-names></name>
<name><surname>Giles</surname><given-names>F.</given-names></name>
<name><surname>Ravandi</surname><given-names>F.</given-names></name>
<name><surname>Cortes</surname><given-names>J.</given-names></name>
<name><surname>Wierda</surname><given-names>W. G.</given-names></name>
<name><surname>Ouzounian</surname><given-names>S.</given-names></name>
<name><surname>Quezada</surname><given-names>A.</given-names></name><etal/>
</person-group>. <article-title>Safety and Clinical Activity of the Combination of 5-Azacytidine, Valproic Acid, and All-Trans Retinoic Acid in Acute Myeloid Leukemia and Myelodysplastic Syndrome</article-title>. <source>Blood</source> <year>2007</year>, <volume>110</volume>, <fpage>2302</fpage>–<lpage>2308</lpage>.</citation>
</ref>
<ref id="bibr178-1087057111421212">
<label>178.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raza</surname><given-names>A.</given-names></name>
<name><surname>Mehdi</surname><given-names>M.</given-names></name>
<name><surname>Mumtaz</surname><given-names>M.</given-names></name>
<name><surname>Ali</surname><given-names>F.</given-names></name>
<name><surname>Lascher</surname><given-names>S.</given-names></name>
<name><surname>Galili</surname><given-names>N.</given-names></name>
</person-group> <article-title>Combination of 5-Azacytidine and Thalidomide for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia</article-title>. <source>Cancer</source> <year>2008</year>, <volume>113</volume>, <fpage>1596</fpage>–<lpage>1604</lpage>.</citation>
</ref>
<ref id="bibr179-1087057111421212">
<label>179.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scott</surname><given-names>B. L.</given-names></name>
<name><surname>Ramakrishnan</surname><given-names>A.</given-names></name>
<name><surname>Storer</surname><given-names>B.</given-names></name>
<name><surname>Becker</surname><given-names>P. S.</given-names></name>
<name><surname>Petersdorf</surname><given-names>S.</given-names></name>
<name><surname>Estey</surname><given-names>E. H.</given-names></name>
<name><surname>Deeg</surname><given-names>H. J.</given-names></name>
</person-group> <article-title>Prolonged Responses in Patients with MDS and CMML Treated with Azacitidine and Etanercept</article-title>. <source>Br. J. Haematol</source>. <year>2010</year>, <volume>148</volume>, <fpage>944</fpage>–<lpage>947</lpage>.</citation>
</ref>
<ref id="bibr180-1087057111421212">
<label>180.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borthakur</surname><given-names>G.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Kantarjian</surname><given-names>H.</given-names></name>
<name><surname>Faderl</surname><given-names>S.</given-names></name>
<name><surname>Ravandi</surname><given-names>F.</given-names></name>
<name><surname>Ferrajoli</surname><given-names>A.</given-names></name>
<name><surname>Torma</surname><given-names>R.</given-names></name>
<name><surname>Morris</surname><given-names>G.</given-names></name>
<name><surname>Berry</surname><given-names>D.</given-names></name>
<name><surname>Issa</surname><given-names>J. P.</given-names></name>
</person-group> <article-title>Report of a Phase 1/2 Study of a Combination of Azacitidine and Cytarabine in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes</article-title>. <source>Leuk. Lymphoma</source> <year>2010</year>, <volume>51</volume>, <fpage>73</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr181-1087057111421212">
<label>181.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mack</surname><given-names>G. S.</given-names></name>
</person-group> <article-title>To Selectivity and Beyond</article-title>. <source>Nat. Biotechnol</source>. <year>2010</year>, <volume>28</volume>, <fpage>1259</fpage>–<lpage>1266</lpage>.</citation>
</ref>
<ref id="bibr182-1087057111421212">
<label>182.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kummar</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>H. X.</given-names></name>
<name><surname>Wright</surname><given-names>J.</given-names></name>
<name><surname>Holbeck</surname><given-names>S.</given-names></name>
<name><surname>Millin</surname><given-names>M. D.</given-names></name>
<name><surname>Tomaszewski</surname><given-names>J.</given-names></name>
<name><surname>Zweibel</surname><given-names>J.</given-names></name>
<name><surname>Collins</surname><given-names>J.</given-names></name>
<name><surname>Doroshow</surname><given-names>J. H.</given-names></name>
</person-group> <article-title>Utilizing Targeted Cancer Therapeutic Agents in Combination: Novel Approaches and Urgent Requirements</article-title>. <source>Nat. Rev. Drug Discov</source>. <year>2010</year>, <volume>9</volume>, <fpage>843</fpage>–<lpage>856</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>